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Zusammenfassung
Die Mehrfache Chemotherapieresistenz (Multidrug Resistance) wird als die
Fähigkeit definiert , die von mehreren Zelltypen erworben werden kann, um sich gegen
die tödliche Wirkung von zytotoxischen Substanzen zu wehren. Dies beruht auf
vermehrtem Transport von Xenobiotika aus der Zelle, was zu einer dramatischen
Verringerung der intrazellulären Konzentration von chemotherapeutischen Substanzen
führt. Dieser Effekt wird durch die Expression von transmembranen Transporter-
Proteinen, die vor allem der ABC-Familie angehören, verursacht. Zu dieser Familie
gehören z.B. das P-Glykoprotein (P-gp, auch MDR1, multidrug resistance protein
genannt) und MRP1, die eine große Vielfalt an Substraten transportieren können.
Diese Transporter benötigen bestimmte strukturelle Elemente, die die
Funktionsweise der Transporter vermitteln. die Anwesenheit von mindestens zwei
transmembranen Domänen (TMD), jeweils gefolgt von einem ATP-Bindungsmodul
(ABC). MRP1 ist ein 190 kDa Glykoprotein mit einer vermuteten Topologie, die eine
zusätzlich zum typischen P-gp ähnlichen Kern eine amino-proximale transmembrane
Domäne aufweist, die für die meisten MRP-Proteine charakteristisch ist.
Diese Domäne besteht aus fünf transmembranen Alpha-Helices und besitzt
einen extrazellulären N-Terminus (Bàkos et al., 1996; Hipfner et al., 1997; Kast, Gros,
1997). Sie ist durch einen cytoplasmatischen Verbindungs-Loop (L0) mit dem P-gp
ähnlichen Kern verbunden. Wenn MRP1 in polarisierten Zellen exprimiert wird, wird es
zu der basolateralen Membran geleitet.
MRP1 besitzt typische Eigenschaften einer GS-X Pumpe, manchmal auch
MOAT (multispecific organic anion transporter) genannt. GS-X Pumpen haben eine
relativ große Substrat-Spezifizierung. Sie transportieren typischerweise anionische
Glutathion-, Glucuronat- oder Sulfat-Konjugate. Außerdem ist MRP1 fähig,
unmodifizierte hydrophobische Substanzen wie natürlich produzierte
Chemotherapeutika gleichzeitig mit reduziertem Gluthathion (GSH) zu transportieren.
Funktionale Studien haben bewiesen, dass   auch beim Transport von Vincristin (Loe et2
al., 1998; Renes  et al, 1999) und Daunorubicin (Salerno und Garnier-Suillerot, 2001)
ebenfalls  GSH von MRP1 ko-transportiert wird.
Um die Rolle der N-terminalen Regionen in der Funktion des MRP1 zu
untersuchen, haben Bàkos et al.,1998, verkürzte MRP1 Varianten hergestellt. Diese
Mutanten bestehen entweder 1) nur aus dem P-gp ähnlichen Kern (∆ MRP1) oder aus
dem Kern plus dem Verbindungs-Loop L0  (L0∆ MRP1). Die Konstrukte wurden in
baculovirus-infizierten Insektenzellen und in polarisierte MDCKII (Madin-Darby
canine kidney)-Zellen exprimiert. Es wurde untersucht, ob die Fähigkeit dieser
Deletionsmutanten MRP1-Substrate zu transportieren, sowie deren subzellulare
Lokalisation in den MDCKII-Zellen untersucht. Der P-gp ähnliche Kern (∆ MRP1) war
inaktiv. Durch indirekte Immunofluoreszenz wurde gezeigt, dass die Expression der
∆ MRP1 in MDCKII-Zellen auf intrazellulare Bereiche beschränkt war.
Entgegen der Vermutung verhielt sich L0∆ MRP1 wie das wild-type MRP1 in
Transport-Experimenten und es wurde korrekt zu der basolateralen plasmatischen
Membrane in der MDCKII-Zelle geführt. Dies könnte andeuten, dass die erste
transmembrane Domäne (TMD0) weder für die Funktion des MRP1 noch für das
Routing des Proteins benötigt wird. Diese Ergebnisse sind in Fig. 1.5 in der Dissertation
zusammengefasst.
Diese Ergebnisse erlauben die Annahme, dass der zytoplasmatische
Verbindungs-Loop L0  eine funktionale Domäne bildet, die für die durch MRP-1
vermittelte Transportaktivität und für die Lokalisation des Proteins in polarisierten
Zellen notwendig und ausreichend ist. Bemerkenswert ist, dass in allen bis heute
identifizierten Mitgliedern der MRP Familie L0 konserviert ist.
In der vorliegenden Arbeit sollte nun die Funktion des amino-terminalen
Bereichs von MRP1, der aus der ersten transmembranen Domäne TMD0  und dem
cytoplasmischen Verbindungs-Loop L0 besteht, untersucht werden. Wir haben durch
Expression und Koexpression von diversen MRP1 Mutanten in polarisierten MDCKII
Zellen nach Bereichen gesucht, die für das Routing des MRP1 in der basolateralen
plasmatischen Membrane verantwortlich sind.3
In Bàkos et al., 2000, wird beschrieben, wie gekürzte und mutierte MRP1
Moleküle konstruiert worden sind und ihr Verhalten wird charakterisiert. Dabei wurden
sie in den folgenden zwei Systemen exprimiert: 1) in baculovirus-infizierten
Insektenzellen und 2) in MDCKII - Zellen.
Im ersten Teil dieser Arbeit wurden die Mutanten, die in MDCKII-Zellen
exprimiert worden sind, zunächst näher charakterisiert.
Charakterisierung der MDCKII-MRP1∆∆∆∆ (223-232) Zelllinie
Durch die Vorhersage der sekundären Struktur wurde die Anwesenheit einer
amphipathischen Helix innerhalb der L0 Region vermutet. Es wurde gezeigt, dass in der
L0 Region aller Mitglieder der MRP Familie solch eine Helix vorhanden ist. Um
festzustellen, ob diese Helix für die Transportaktivität und/oder dem Routing wesentlich
ist, haben wir eine 10-Aminosäure-Deletion ∆ (223-232) innerhalb dem vollständigen
MRP1 und eine stabile MDCKII-MRP1 ∆ (223-232) Zelllinie durch retrovirale
Transduktion hergestellt. Das Protein wurde korrekt N-glycosyliert (Fig. 4.4 in der
Dissertation). Durch Immunolokalisation wurde gezeigt, dass das Routing nicht durch
die Mutation beeinflusst wurde (Fig. 4.5 in der Dissertation).
Signifikant dabei ist, dass die Mutante nicht fähig war, MRP1 Substrate zu
transportieren. Dies deutet darauf hin, dass die fehlende Helix für die Funktionalität der
MRP1 notwendig ist. In-Vitro- Experimente im Baculo-System (Bàkos et al., 2000)
haben gezeigt, dass die amphipatische Helix an der Anbindung des MRP1 an der
Membrane teilnimmt.
Koexpression des cytoplasmatischen Verbindungs-Loop L0  mit  ∆∆∆∆ MRP1 in
MDCKII Zellen
Um weitere Untersuchungen über die Rolle des zytoplasmatischen Verbindungs-
Loops L0 anzustellen, haben wir L0 zusammen mit dem inaktiven C-terminalen Kern
von MRP1, ∆ MRP1, in MDCKII - Zellen koexprimiert (Fig. 4.8 in der Dissertation).
Durch Immunolokalisation wurde festgestellt, dass ein Routing des Peptids zu der4
plasmatischen Membrane in polarisierten Zellen stattfindet (Fig. 4.10 in der
Dissertation).
Es war uns nicht möglich, einzelne MDCKII-Klone zu isolieren.
Wahrscheinliche Gründe sind die Instabilität des Peptids und seine rapide
Degradierung. Daher konnte die Transportaktivität der koexprimierten Mutanten in den
MDCKII-Zellen nicht gemessen werden.
Dennoch wurde im Baculo-System gezeigt, dass die Koexpression der zwei
Konstrukte in einer MRP1-ähnlichen Aktivität resultiert (Bàkos et al., 2002).
Diese Ergebnisse zusammengenommen suggerieren verstärkt, dass das isolierte
L0-Peptid in der Lage ist, sich mit ∆ MRP1 zu assoziieren. Dadurch erlangt das Protein
wieder seine Funktion und lokalisiert sich in der basolateralen Membrane.
Charakterisierung des N-terminalen Bereichs des MRP1 (TMD0L0) in MDCKII
polarisierten Zellen.
Um die Schwierigkeiten bei der Isolierung von MDCKII-L0  Klonen zu
umgehen, wurde eine MDCKII-Zelllinie, die das Polypeptid TMD0L0 (Aminosäure 1-
281) exprimiert, hergestellt. Das Polypeptid TMD0L0 besteht aus der ersten
transmembranen Domäne TMD0, die um den intrazellularen Verbindungs-Loop L0
erweitert wurde (Fig. 4.11, Paneel A, in der Dissertation). Durch indirekte
Immunofluoreszenz (Fig. 4.12 in der Dissertation) und durch die Methode der
Biotinylierung der Zelloberfläche (Fig. 4.15 in der Dissertation) wurde festgestellt, dass
dieses Protein sich teilweise in der basolaterale Membrane befindet.
Koexpression von TMD0L0 und ∆∆∆∆ MRP1 in MDCKII polarisierten Zellen.
Die Mutanten TMD0L0 und ∆ MRP1 wurden in MDCKII-Zellen koexprimiert
(Fig. 4.16, in der Dissertation). Die beiden Peptide  ergeben zusammen ein
vollständiges MRP1-Molekül.5
Die Anwesenheit von TMD0L0 genügte, um die Glycosilierung des ∆ MRP1 (Fig.
4.17 in der Dissertation) und die Lokalisierung in der basolateralen Membrane des
∆ MRP1 zu ermöglichen (Fig. 4.18 in der Dissertation).
Außerdem resultierte die Koexpression der zwei komplementären MRP1-
Fragmente in einer wild-type-ähnlichen Transportaktivität (Fig. 4.19 in der
Dissertation). Es wurde mittels einer Koimmunoprezipitation gezeigt, dass die beiden
Fragmente des MRP1 interagieren (Fig. 4.21 in der Dissertation).
Charakterisierung des chimerischen Konstruktes TMD0(MRP1)L0(MRP2) in
MDCKII-Zellen
MRP2 ist ein Homolog von MRP1, welches in der apikalen Membrane von
polarisierten Zellen lokalisiert ist.
Um zu untersuchen, ob das Signal für die basolaterale Lokalisation von MRP1
in L0 enthalten ist, wurde ein chimerisches Protein hergestellt, welches aus TMD0 von
MRP1 und L0  von MRP2 besteht und in MDCKII und MDCKII-∆ MRP1 Zellen
exprimiert.
Da dieses chimerische Protein durch Endoglycosidase H deglycosiliert werden
konnte, wurde festgestellt, dass das unvollständig glycosiliert ist (Fig. 4.24 in der
Dissertation) und dass es sich im endoplasmatischen Reticulum lokalisiert. Die
intrazelullare Lokalisation der Chimera in An- und Abwesendheit von ∆ MRP1 wurde
durch Immunolokalisation bestätigt (Fig. 4.25 in der Dissertation).
Schlussfolgerungen
In dieser Arbeit wurden durch Expression und Koexpression diverser MRP1
Mutanten in polarisierten MDCKII-Zellen Bereiche gesucht, die für das Routing von
MRP1 wichtig sind. Signale für die basolaterale Lokalisation von transmembranen
Proteinen sind sehr unterschiedlich und diverse molekulare Signale nehmen an der
Bestimmung des Routings teil. Im Falle von MRP1 wurde durch die Studien in dieser6
Arbeit erkannt, dass die zytoplasmatische Verbindungs-Loop L0 von MRP1 ein Signal
enthalten könnte, welches zur basolateralen Lokalisation des Proteins beiträgt. Es war
nicht möglich, eine exakte Sequenz zu bestimmen. In MRP1 sind keine der bisher
kodifizierten Motive vorhanden. Eine extensive Untersuchung mittels weiterer
Mutanten von MRP1, ergänzt durch Studien über MRP1/MRP2 chimerische Proteine
sind notwendig, um die Determinanten für das Routing von MRP1 festzustellen.
Es wurde eine Alpha-Helix innerhalb des Verbindungs-Loops L0 identifiziert,
die für die Funktionalität von MRP1 als Transporter wichtig ist. Gleichzeitig wurde
gezeigt, dass das Routing des Proteins nicht durch die Mutation beeinträchtigt wurde.
Das bedeutet, dass ein korrektes Routing keine ausreichende Bedingung für die
Funktionalität des MRP1 ist.
Die Interaktion von zwei komplementären MRP1-Fragmenten TMD0L0  und
∆ MRP1 wurde nachgewiesen. Sie stabilisieren sich gegenseitig und bilden  ein
funktionsfähiges MRP1 Molekül. Da TMD0L0 dazu beiträgt, das basolaterale Routing
von ∆ MRP1 zu ermöglichen, wird die Hypothese zusätzlich bestätigt, dass L0 eine
wichtige Funktion in der korrekten Lokalisation des MRP1 in der plasmatischen
Zellmembrane übernimmt.
Die in dieser Arbeit gewonnen Erkenntnisse können somit dazu beitragen, die
Funktionsweise des systems der Mehrfachen Chemotherapieresistenz in Säugerzellen
besser zu verstehen, so dass bei der Therapie diverser Erkrankungen, bei denen der
Transport von Chemotherapeutika aus den Zielzellen unterbunden werden soll, das
Transportsystem entsprechend beeinflusst werden kann.7
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1  INTRODUCTION
1.1  Multidrug resistance
Cells exposed to toxic compounds can develop drug resistance by a number of
mechanisms including decreased uptake, resistance against apoptotic signals, increased
detoxification, alteration of target proteins, or increased excretion. Some of these
mechanisms can lead to multidrug resistance (MDR) in which cells gain resistance
against a whole range of drugs in addition to the drug to which they were originally
exposed, a feature first described by Kessel et al. in 1968 (Kessel et al., 1968; Biedler
and Riehm, 1970). One form of MDR is called classical multidrug resistance. Classical
MDR was defined as the phenomenon that mammalian cells could become resistant to a
range of cytotoxic drugs that do not share a common target or structure, after selection
with a single drug. Whereas the capacity of cells to become MDR is conserved
throughout evolution, in this thesis I will concentrate on transport proteins, which
overproduction can result in drug resistance in mammalian cancer cells. MDR cell lines
show an increased efflux of cytotoxic drugs from the cell by the overexpression of
transporter molecules, resulting in a decreased intracellular drug concentration. The
transporters responsible for the active extrusion of drugs are members of the ATP-
binding cassette (ABC) transporter superfamily. The ABC-transporters represent the
largest family of transmembrane proteins. Proteins are classified as ABC-transporters
based on the sequence and organization of their ATP-binding domains, also known as
nucleotide binding folds (NBFs).  The NBFs contain characteristic motifs called Walker
A, C and B, separated over 90-120 amino acids (Walker et al., 1982). Functional
transporters typically contain two cytoplasmically localized NBFs and at least two
transmembrane domains. In humans currently 51 ABC-proteins have been identified
(Müller, http://nutrigene.4t.com/humanabc.htm), at least six of which have been
associated with drug transport. All human and mouse ABC genes have a standard
nomenclature and are subdivided in seven classes (ABCA-ABCG; Dean et al., 2002).
Synonymous gene names are still used, however. The first ABC-transporter identified13
whose overexpression caused MDR to a range of drugs in tumor cells was MDR1 P-
glycoprotein (Pgp) or ABCB1 (Juliano and Ling, 1976; Chen et al., 1986; Roninson et
al., 1986). MDR1 Pgp is an approximately 170-kDa glycosylated transmembrane
protein that consists of two similar halves each containing six transmembrane spanning
domains and a cytosolically localized C-terminal ATP-binding domain. MDR1 Pgp has
to be localized in the plasma membrane in order to cause drug resistance. MDR1 Pgp
has been shown to be a promiscuous transporter transporting a wide range of
hydrophobic amphipathic compounds. Examples of cytotoxic drugs transported by
MDR1 Pgp are anthracyclines, Vinca alkaloids, colchicine, cyclosporine A and taxol,
drugs with different cellular targets and chemical structures.
As not all multidrug resistant cells showed overexpression of Pgp, a search for
other efflux pumps was initiated, leading to the identification of the multidrug resistance
protein MRP1 (ABCC1; Cole et al., 1992). Subsequently it was shown that MRP1 is
member of a larger family (Kool et al., 1997) some of which have been shown to be
able to transport at least some drugs. Since MRP proteins are the subject of this thesis,
they will be discussed extensively in paragraph 1.3. Other ABC proteins that have been
associated with drug resistance are: (i) The breast cancer resistance protein (BCRP,
MXR, ABCP or ABCG2), which was cloned from cells resistant to mitoxantrone
(Miyake et al., 1999; Ross et al., 1999). (ii) A distant homolog of MDR1 Pgp, sister of
Pgp or the bile salt export protein (BSEP or ABCB11) confers low level resistance to
paclitaxel in liver cells (Childs et al., 1998).
Identification of the upregulated genes in different resistant tumors and detailed
knowledge of the causes and the mechanisms of drug resistance will allow predicting
the response of patients to chemotherapy.14
1.2  The human ABC gene family
1.2.1  Structure / activity relationship
Chang and Roth (2001) elucidated for the first time the high resolution structure
by x-ray crystallography of a complete ABC transporter, the MsbA lipid A transporter
from Escherichia coli. By sequence homology MsbA is more closely related to the
mammalian MDR1 Pgp than any other bacterial ABC-transporter (Tomii and Kanehisa,
1998).
The msbA gene encodes a half transporter that consists of six membrane
spanning regions and a nucleotide-binding domain located at the cytoplasmic side of the
cell membrane. MsbA is assembled as a homodimer with a total molecular mass of 129
kDa (Doerrler et al., 2001; Karow and Georgopoulos, 1993). MsbA transports lipid A, a
major component of the bacterial outer cell membrane (Zhou et al., 1998).
The crystal structure confirmed the prediction that the half transporter is
organized as a homodimer in the cell, with each subunit containing two domains, a
TMD composed of six α -helices and one NBD. The chamber is formed between two
angled blocks of six α -helices that correspond to the two TMDs and is closed at the
extracellular face of the membrane. The chamber surface facing the inner leaflet is rich
in positively charged amino acids, while the surface facing the outer leaflet is much
more hydrophobic. The chamber has two large side entrances between the TMDs that
would be accessible from the inner leaflet of the bilayer. These side entrances are
consistent with evidence that Pgp extracts substrates from the inner leaflet of the lipid
bilayer and transports them directly in the extracellular aqueous medium.
Figure 1.1 indicates the structural organization of Eco-MsbA hypothesized by
Chang and Roth.15
Fig. 1.1. Structure of Eco-msbA.
Representation of the dimer forming the chamber opening. The transmembrane domain, the nucleotide
binding domain, and intracellular domain are colored red, dark blue and light blue respectively.
Chang and Roth propose a possible flipping mechanism for the transport of lipid
A based on the structure of MsbA that could be generally valid for the members of the
MDR-ABC transporter group. The entrance of lipid A from the inner leaflet of the
plasma membrane into the chamber induces some conformational changes in the TMDs
that are transferred to the NBDs via the intracellular domain. This change initiates the
hydrolysis of ATP, with as a consequence closing of the chamber. The hydrophobic
substrate in the chamber is in an energetically unfavorable environment as it is in close
proximity to the positively charged residues of the transmembrane domains. To switch
to a more favorable condition, the substrate flips to the outer leaflet of the lipid bilayer
or directly into the aqueous space.
This model is not completely consistent with the low resolution structure of Pgp
and of MRP1, which chambers seem to be widely open at the extracellular side of the
plasma membrane (Rosenberg et al., 1997, 2001a). It has been shown for the bacterial
transporter LmrA, a phosphatidylethanolamine transporter, that the substrate passes
from the inner leaflet of the lipid bilayer directly to the outside of the cell (Bolhuis et
al., 1997); consequently the chamber should be open to the extracellular side.
Additionally this model would not explain how hydrophilic substances, like e.g. sugars,
or in the case of the channel CFTR (or ABCC7), the cystic fibrosis transmembrane
conductance regulator, ions, could pass the membrane.
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There are questions that still remain open, for example, how exactly ATP
hydrolysis and the conformational changes in the transmembrane domains are coupled,
and not much is known about the TMDs, the substrate binding sites, and their
conformational changes during the catalytic cycle. There is evidence indicating that the
NBDs work in alternation, but it is not known whether they interact directly (Higgins
and Linton, 2001). Rosenberg et al., (Rosenberg et al., 2001b) brought some light into
these questions by generation two-dimensional crystals of Pgp blocked in different steps
of the catalytic cycle. They observed that the membrane spanning domains undergo
structural reorganization after ATP binds to the NBDs. Consequently, the affinity for
drug binding decreases suggesting that the binding of ATP provides the initial energy
for the translocation. After ATP hydrolysis, ADP and phosphate are released, and the
transporter returns to the initial configuration. Higgins and Linton (2001) proposed
different possible working models for ABC transporters, which are summarized in fig.
1.2.
Fig. 1.2. Conformational changes induced during the transport cycle in an ABC transporter proposed by
Higgins and Linton, 2001.
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The authors suggest two models for how a substrate-binding site may be
reorientated to allow export of a substrate from the cell. According to the “tilting”
model, shown in the top figure, the substrate enters the inner leaflet of the membrane
and from there the chamber. Following ATP-binding and hydrolysis a conformational
change occurs in the transporter and resulting in export of the substrate out of the cell.
For MsbA a variation of the “tilting model” is suggested: the chamber is lipid-filled so
that it does not open to the external aqueous phase but reorientates so that the substrate
is directed towards the outer leaflet of the bilayer. In the “rotational model” shown in
the bottom of the picture, twisting of the transmembrane α -helix reorientates the
substrate-binding site from the inner leaflet of the membrane bilayer, where the
substrate can bind, to the aqueous chamber. From there the solute is released and can
either exit the cell or partition into the outer leaflet of the bilayer.
1.2.2  Physiological role of ABC transporters
Although several human ABC transporters have been demonstrated to be
involved in multidrug resistance in tumor cells, they are widely distributed in normal
tissues and transport a wide range of (endogenous) substrates (Gottesman et al., 2002).
An important function is controlling the permeability of the central nervous system. The
blood-brain barrier (BBB), which protects the central nervous system from toxins, is
composed of endothelial cells on the blood capillaries. MDR1 Pgp is localized in the
apical (luminal) membrane of the endothelial cells, preventing toxins from entering the
brain (Schinkel et al., 1994, 1996; Xie et al., 1999). MRP1 is localized in the choroid
plexus (Rao et al., 1999); mouse Mrp1 has been found in the testicular tissue as well as
Pgp (Wijnholds et al., 1998; Melaine et al., 2002). In placenta, MDR1 Pgp is localized
on the apical syncytiothrophoblast, where it protects the fetus against toxic cationic
xenobiotics. Also MRP1 and the half transporter ABCG2 are localized in placenta
(Maliepaard et al., 2001).
ABC transporters expressed in liver, kidney and the gastrointestinal tract protect
the organism against toxic agents. In the canalicular membrane of hepatocytes MDR118
Pgp transports toxins from the liver into bile (Schinkel et al., 1997), while MRP2
transports bilirubin glucuronide and other organic anions into the bile (König et al.,
1999a). Other ABC proteins expressed in hepatocytes at relevant levels are ABCB11
(also known as BSEP) (Strautnieks et al., 1998), and MDR2 (Smit et al., 1993; Ruetz
and Gros, 1994). Gastrointestinal mucosal cells contain MDR1 Pgp in the apical
membrane that faces the intestinal lumen, establishing a barrier against absorption of
toxins, and limiting oral bioavailability of some drugs (Greiner et al., 1999; Smit et al.,
1998; Sparreboom et al.1997; Mayer et al., 1997; van Asperen et al., 1999; Kruijtzer et
al., 2002). In general MDR1 Pgp seems to have a protecting function against toxic
compounds and metabolites in specific organs like the blood brain barrier, intestine,
testis, and placenta.
1.3  The MRP family of transporters
Generally xenobiotics are metabolized to more hydrophilic compounds to
facilitate their excretion. Hepatic enzymes induce two metabolism pathways. In phase I
substances are modified by members of the cytochrome P450 family with a hydroxylic
group via oxidation, reduction, hydrolysis or hydration. Metabolites or parent
compounds can also be conjugated to glutathione, glucuronide or sulfate in phase II.
Such chemical modifications allow elimination of the drug but they also interfere with
its biological activity, decreasing or sometimes increasing toxic effects. The resulting
conjugates are too hydrophilic to diffuse out of the cell and require dedicated
transporters to extrude them. It was postulated that ABC transporters would be
responsive for such transport activity, but since the substrates of MDR1 Pgp are
typically non-anionic it was concluded that other pumps able to transport anionic
conjugates should exist (Ishikawa, 1992).
MRP1 was shown to mediate the ATP-dependent unidirectional transport of
lipophilic substances conjugated to glutathione, glucuronate or sulfate (Jedlitschky et
al., 1996). In addition a number of unconjugated amphiphilic anions are transported,
like the acetoxymethyl ester and the free anion forms of the fluorescent dye calcein, the19
organic anion anticancer agent methotrexate and several other cytotoxic drugs (Zaman
et al., 1994; Hollo et al., 1996; Bàkos et al., 2000b). The discovery of MRP1 initiated a
search for homologues that resulted in the identification of eight additional proteins that
showed homology to MRP1. Phylogenetic analyses confirmed that the MRP1-like
proteins belonged to a novel branch of the ABC superfamily. In 1996 the gene of
cMOAT (now MRP2; ABCC2) was cloned from rat liver cDNA libraries (Paulusma et
al., 1996; König et al., 1996); in 1997 MRP3 (ABCC3), 4 (ABCC4) and 5 (ABCC5)
followed (Kool et al. 1997). Recent work has added four more members to the MRP
family: MRP6 (ABCC6; Kool et al., 1999a), MRP7 (ABCC10; Hopper et al., 2001),
and MRP8 (ABCC11) and 9 (ABCC12; Tammur et al., 2001).
MRP RNAs exhibit different patterns of tissue distribution and most MRP
proteins are encoded by genes located on different chromosomes (Table 1.1). While
MRP1 and MRP5 are ubiquitous in the human body, the tissue expression patterns of
MRP3 and MRP6 are similar to the tissue distribution of MRP2. The MRP6 gene is
located on chromosome 16 next to the MRP1 gene (Kool et al., 1999a). Recently,
MRP8  and MRP9 were identified adjacent to each other on chromosome 16q12.1
(Tammur et al., 2001; Bera et al. 2002).
Chromosomal
localization
Tissue distribution Subcellular localization
MRP1 16p13.1 Ubiquitous basolateral
MRP2 10q24 Liver, kidney, gut apical
MRP3 17q21.3 Pancreas, kidney, gut,
liver, adrenal
basolateral
MRP4 13q32 Prostate, testis, ovary, gut,
pancreas, lung, muscle
still unclear
MRP5 3q27 Ubiquitous basolateral
MRP6 16p13.1 Liver, kidney basolateral
MRP7 6p21 Colon, skin, testis unknown
MRP8 16q12.1 Breast, testis, liver, brain,
placenta
unknown
MRP9 16q12.1 Brain, testis, ovary,
skeletal muscle, pancreas
unknown
Table 1.1. Chromosomal localization, tissue distribution  and subcellular localization of MRP proteins20
The MRP proteins differ from MDR1 Pgp in their membrane topology. MRP1,
2, 3, 6 and 7 contain an additional amino-proximal membrane-spanning domain
predicted to consist of 5 transmembrane α -helices. MRP4, 5, 8 and 9 lack this first
domain but contain an intracellular amino-terminal loop extending the typical secondary
structure of most human full-length ABC proteins at the N-terminus. The predicted
membrane topology of the various MRP family members is shown in figure 1.3.
TMD0 L0 TMD1 TMD2 ABC ABC
MRP1, MRP2,
MRP3, MRP6
MRP7
MRP4, MRP5,
MRP8, MRP9
Fig. 1.3. Membrane topology models of the MRP family..
TMD: transmembrane domain; L0: linker; ABC: ATP binding cassette
Like many other ABC-transporters that are localized in the plasma membrane, in
polarized cells they are routed to either the apical or basolateral plasma membrane.
Therefore the transported substrates accumulate in a specific compartment. While P-
glycoprotein and MRP2 are localized in the apical plasma membrane, MRP1, MRP3,
MRP5 and MRP6 are localized in the basolateral membrane (Evers et al., 1996;
Paulusma et al. , 1996; Buchler et al., 1996; König et al., 1999b; Kool et al. 1999b;
Wijnholds et al., 2000b; Madon et al., 2000). Currently nothing is known about the
subcellular distribution of the remaining MRP family members MRP7-9 and that of
MRP4 is still controversial21
1.3.1  An inventory of the MRP family members
1.3.1.1  MRP1
The multidrug resistance protein, MRP1, was discovered in 1992 in H69AR
cells, a small cell lung cancer cell line that displayed a multidrug resistance phenotype
in absence of Pgp. These cells showed relatively high levels of resistance to the Vinca
alkaloids, epipodophyllotoxins, doxorubicin, mitoxantrone, daunorubicin, epirubicin
and colchicine (Mirski et al.,1987; Cole, 1992). MRP1 mRNA was overexpressed 100-
200 fold in comparison to the parental H69 cell line from which H69AR is derived
(Cole et al., 1992). In addition MRP1 was found to be overexpressed in a doxorubicin-
selected multidrug resistant HeLa cell line that did not overexpress Pgp. In both cell
lines the MRP1 gene was amplified (Slovak, 1993). By sequence analysis the 1531
amino acid protein was identified as a member of the ABC superfamily.
Newly synthesized MRP1 migrates on SDS-polyacrylamide denaturing gels as a
protein with an apparent molecular weight of about 170 kDa. This immature
polypeptide is processed to a 190-kDa mature form by addition of N-linked sugar
residues (Almquist et al., 1995). Sequence analysis of MRP1 indicates that there are 14
potential N-glycosylation sites, distributed over both halves of the molecule. Mutation
studies (Hipfner et al., 1997) demonstrated that Asn 19 and Asn 23 are glycosylated, in
accord with the extracellular localization of the N-terminus. Asn 1006 in TMD2 was
identified as a third functional N-glycosylation site. Several MRP-related proteins and
CFTR contain glycosylation sequons at similar locations.
The topology of MRP1 was studied using epitope insertion methodology.
Hemagglutinin (HA) epitope tags were inserted at various locations and their orientation
was determined in permeabilized and non-permeabilized cells expressing the MRP1
mutants. Based on these studies a topological model for MRP1 was proposed. MRP1
was predicted to consist of three transmembrane domains, the first containing five
membrane spanning α - helices. The other two transmembrane domains each contain six22
helices, followed by a nucleotide binding domain (Kast  and Gros , 1997, 1998; Hipfner
et al. 1997).
1.3.1.1.1  Transport activity of MRP1
MRP1 is able to transport glutathione conjugates, such as dinitrophenyl
glutathione (DNP-GS) and leukotriene C4 (LTC4)(Jedlitschky et al., 1994; Leier et al.,
1994; Müller et al., 1994). Transporters with this characteristic are called GS-X pumps,
or multispecific organic anion transporter (MOAT). GS-X pumps have a relatively
broad substrate specificity; they typically transport glutathione, glucuronate or sulfate
conjugates. ATP-dependent uptake of numerous endogenous and exogenous conjugated
organic anions  into inside-out membrane vesicles isolated from several cell types
overexpressing MRP1 was reported (Müller et al., 1994; Leier et al., 1994; Keppler ,
1997; Suzuki , 1998).
It was observed that overexpression of MRP1 cDNA in human lung carcinoma
cells caused an increased efflux of reduced GSH in the presence of arsenite (Zaman et
al., 1995); Probably arsenite is transported together with glutathione as a short lived
complex. Interestingly, the transport of at least three authentic organic anions,
glucuronosyl-etoposide (Sakamoto et al., 1999), estrone-3-sulfate (Qian et al., 2001),
and the glucuronosyl derivative of a nicotine-derived carcinogen, NNAL-O-glucuronide
(Leslie et al., 2001), is greatly enhanced by physiological concentrations of GSH. A role
of GSH in the export of compounds by MRP1 is supported by studies using buthionine
sulfoximine (BSO). BSO is a potent inhibitor of γ -glutamylcysteine synthase, the
enzyme catalyzing the first rate limiting step of the biosynthesis of GSH. Treatment of
cells with BSO results in a drastic reduction of the intracellular GSH pool. In several
studies with MRP1 overexpressing cells BSO treatment resulted in an increased drug
accumulation and toxicity, suggesting that the modulation of MRP1 activity by BSO is
a direct result of GSH depletion (Vanhoefer et al., 1997; Versantvoort et al., 1995;
Zaman et al., 1995; Draper et al. 1997). Given that MRP1 is a GS-X pump, it was not
expected to transport chemotherapeutic drugs like anthracyclines and Vinca alkaloids,23
compounds not known to be conjugated to negatively charged ligands. It was speculated
that MRP1 confers drug resistance by elimination of conjugation products from cells
(Cole and Deeley, 1998). There are some problems associated with this model of
MRP1-mediated drug resistance. Metabolic conjugation to GSH is a detoxification
pathway producing more water-soluble and often less toxic metabolites. This implicates
that increased elimination of such drug metabolites may result in drug resistance only if
their transport out of the cell is the rate limiting step. In addition, most of the known
substrates of MRP1 are not primarily metabolized by conjugation to GSH. Phase II
metabolism occurs mainly in the liver and intestine and not in several of the tissues in
which MRP1 overexpression confers drug transport. MRP1-mediated resistance to
natural product drugs is not dependent upon phase II metabolism, as only unconjugated
daunorubicin and vincristine are found in the culture medium of MRP1-transfected
resistant cells (Zaman et al., 1995). All these considerations indicated that the transport
of MRP1 could not be limited to that of conjugated compounds.
In vesicle uptake experiments drugs like doxorubicin, daunorubicin, vincristine,
vinblastine, VP-16 or paclitaxel are not able to inhibit transport of LTC4, even at high
concentrations (Müller et al., 1994; Loe et al., 1996). However, Vinca alkaloids can
competitively inhibit transport of LTC4 if relatively high concentrations of reduced GSH
are present (Loe et al., 1996). Subsequently it was demonstrated that transport of
unmodified vincristine is both ATP- and GSH-dependent, being the transport rate in the
absence of GSH very low and not affected by the presence of ATP (Loe et al., 1996,
1998). Functional studies demonstrated that GSH is also substrate of MRP1 if
vincristine (Loe et al., 1998; Renes et al., 1999) and daunorubicin (Salerno and Garnier-
Suillerot, 2001) are transported. Fig. 1.4 shows that MRP1 transports xeno- and
endobiotics following two different mechanisms. It can act as a GS-X pump in synergy
with glutathione-S-transferases, or transport unmodified compounds in association with
unmodified glutathione.24
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Fig. 1.4. Model of the transport activity of MRP1.
After entering the cell, compound X is conjugated to glutathione by a glutathione S-transferase, resulting
in a GS-X conjugate that is actively extruded from the cell by MRP1. Compound Y is not metabolized by
the cell to a negatively charged conjugate and is transported by MRP1 unmodified. Export of
unconjugated compounds by MRP1 is associated with the transport of reduced glutathione. In both cases
transport is depending on the intracellular amount of glutathione.
1.3.1.1.2  Physiological role of MRP1
The MOAT-like transport activity of MRP1 has been well characterized before
its molecular identity was known. A well-characterized substrate of MRP1 is the
cysteinyl leukotriene LTC4 (Ishikawa et al., 1990; Quian et al., 2001; Haimeur et al.,
2002; Ren et al., 2002). This compound is an important chemical mediator in certain
inflammatory responses. LTC4 is a derivative of arachidonic acid, which is conjugated
to glutathione after a series of reactions. Vesicle transport experiments with membranes
derived from MRP1 expressing cells, confirmed that MRP1 is the major high affinity
transporter of LTC4 (Leier et al., 1994; Müller et al., 1994). Subsequently it was
discovered that more endogenous substrates of MOAT are efficiently transported by
MRP1. Examples are glucuronides and sulfate conjugated bile salts (Jedlitschky et al.,
1996), bilirubin glucuronides (Jedlitschky et al., 1997), glutathione disulfide (GSSG)25
(Heijn et al., 1997), the 17β  estradiol 17-(β -D-glucuronide)(Loe et al., 1996),
prostaglandine A2 conjugated with GSH (Evers et al., 1997) and the glutathione
conjugate of 4-hydroxinonenal (4HNE-GS) (Renes  et al., 2000).
Based on the ubiquitous expression of MRP1 and its capacity to transport
anionic conjugates, it was proposed that the physiological function of MRP1 is the
extrusion of detoxification products resulting from phase II metabolism (Müller et al.,
1996). MRP1 could also play a role in oxidative stress. GSSG and 4HNE-GS are
detoxification products generated under conditions of an altered intracellular redox state
(Wang and Ballatori, 1998; Esterbauer et al., 1991), which would suggest that MRP1
takes part in the cellular defense system against oxidative stress (Leier  et al., 1996;
Renes et al., 2000). MRP1 would help to prevent the damaging effects of the rising
GSSG/GSH ratio in cultured rat astrocytes exposed to oxidative stress, as GSSG is
transported more efficiently than GSH (Hirrlinger  et al., 2001). Thus, extrusion of these
metabolites by MRP1 may be required to prevent cellular damage.
The transport of LTC4 and PGA2, molecules involved in inflammation, could be
necessary to react against inflammatory stimuli. Mice lacking Mrp1 show a reduced
response to inflammation induced by a nonspecific inflammatory stimulus (Wijnholds
et al., 1997). These mice are also defective in the trafficking of antigen-bearing
dendritic cells from the epidermis to lymph nodes (Robbiani et al., 2000). Nevertheless,
no pathology has been reported that can be attributed to this effect on dendritic cells and
Mrp1 (-/-) mice are healthy in a protected environment (Wijnholds et al., 1997; Lorico
et al. 1997).
MRP1 is located in intracellular vesicles of undefined nature in e.g.
macrophages (Flens et al., 1996) and in the basolateral membrane of polarized cells
(Evers et al., 1996; Paulusma et al. , 1996), supporting the possibility of MRP1 being a
system of cellular defense rather than one of total organism defense like Pgp and MRP2.
It has been shown that MRP1 is involved in the protection of vital body cavities,
such as the contents of the testicular tubules (Wijnholds et al., 1998) and the
cerebrospinal fluid (Wijnholds et al., 2000a). MRP1 is localized in the basolateral
membrane of the choroid plexus in the brain, where it pumps compounds from the26
cerebrospinal fluid into the blood (Rao et al., 1999; de Lange et al., 2000). Wijnholds et
al., showed that the lack of Mrp1 protein in Mrp1/Mdr1a/Mdr1b triple-knockout mice
causes etoposide levels to increase about 10-fold in the CSF after intravenous
administration of the drug, suggesting that Mrp1 contributes to the blood-CSF drug-
permeability barrier (Wijnholds et al., 2000a).
MRP1 may be part of the blood-testis barrier and cooperate with Pgp to defend
testicular tissue. Pgp is localized in the apical membrane of endothelial cells in the testis
(Melaine et al., 2002), while high amounts of Mrp1 have been found in the basolateral
membrane in mouse Sertoli cells, protecting sperm within the testicular tubules.  Its
absence in Mrp1(-/-) mice leads to an increased drug-induced destruction of sperm cells
(Wijnholds et al., 1998).
MRP1 is also localized in placenta (St-Pierre et al., 2000; Pascolo et al., 2000)
where it participates in the protection of fetal blood against toxic organic anions and
eliminates glutathione/glucuronide conjugates resulting from metabolism (St-Pierre et
al., 2000).
1.3.1.1.3  Inhibitors of MRP1
No potent and specific MRP1 inhibitors are available. So far non-specific
inhibitors of organic anions transport like sulfinpyrazone, probenecid (Evers et al.,
1996) and benzbromarone (Berger et al., 1997) are used to reverse resistance in MRP1
expressing cells. Indomethacin is a nonsteroidal anti-inflammatory drug (NSAID)
(Draper et al., 1997).  It is rapidly conjugated to glucuronide in cells, and it is possible
that this conjugate is transported by MRP1 rather than the free drug. It was shown that
other NSAIDs have a similar effect (Duffy et al., 1998). It has been suggested that
NSAIDs might be used in patients to reverse MRP-mediated drug resistance.
Hooijberg et al. (1999) were able to reverse decreased daunorubicin
accumulation in MRP1 cells with several flavonoids. Nevertheless the cytotoxicity of
these compounds is relatively high; quercetin can reverse vincristine resistance only27
partially and other flavonoids are completely inactive at non-cytotoxic concentrations
(Leslie et al., 2001). It seems unlikely that flavonoids can be modified to yield MRP
inhibitors with sufficient specificity and therapeutic window to be useful in clinical
practice.
Another clinically tested compound, the antagonist of the leukotriene D4
receptor, MK571, is a good MRP1 inhibitor in vesicular transport experiments, but has
only a limited effect on MRP1 in intact cells even at a sub-toxic dose (Gekeler et al.,
1995).
The structural elements that contribute to the affinity of a molecule for MRP1
are not clearly defined, but recognition is partly determined by the number and spatial
distribution of anionic residues (Seelig et al., 2000). Glutathione conjugates have been
used as MRP1 inhibitors of in inside-out membrane vesicles (Furuta et al., 1999). As the
glutathione (GSH) conjugate of ethacrynic acid (EA), GS-EA, is a good substrate of
MRP1 (Zaman et al., 1996), GS-EA derivatives are expected to be good inhibitors of
MRP1. GS-EA analogs demonstrated to inhibit MRP1-mediated [
3H]GS-EA and [
3H]17β  estradiol 17-(β -D-glucuronide) E2-17β G transport in Sf9 vesicles. One of these
compounds inhibits MRP1-mediated efflux of calcein from 2008 ovarian carcinoma
cells overexpressing MRP1. Also resistance of these cells toward methotrexate (MTX)
could be partially reversed by co-incubation with this compound (Burg et al., 2002).
In addition,  certain tricyclic isoxazoles have been found to inhibit ATP-
dependent, MRP1-mediated LTC4 uptake into membrane vesicles and to reverse drug
resistance to MRP1 substrates, such as doxorubicin, in intact HeLa-T5 cells at
micromolar concentration. How these compound work is still not clear, but they might
become a useful tool for research on MRP1 (Norman et al., 2002). Recently an azido
tricyclic isoxazole analog (LY475776) demonstrated to be a potent MRP1-specific
reversing agent, showing GSH dependent inhibition of LTC4 transport. Conversely ATP
hydrolysis can reduce the affinity of MRP1 for LY475776. Recent studies contributed
to understand the structural requirements of this kind of inhibition, characterizing its
GSH dependence, and identifying a potential binding site for the inhibitor (Quian et al.,
2002; Mao et al., 2002).28
1.3.1.2  MRP2
Prior to the cloning of MRP2 (ABCC2), biochemical and genetic studies
indicated that a multispecific organic anion transporter was present in the canalicular
membranes of hepatocytes (König et al., 1999b). Mutant rat strains (TR(-) and EHBR)
lacking this transporter have a hyperbilirubinemic phenotype and impaired secretion of
bilirubin glucuronide, sulfated bile salts, GS-conjugates and GSH into the bile (Suzuki
and Sugiyama, 1998; Oude Elferink et al., 1993). Dubin–Johnson syndrome patients
suffer a form of congenital hyperbilirubinemia caused by mutations in their MRP2 gene
(Paulusma et al., 1997; Trauner et al., 1997; Jedlitschky et al., 1997; Toh et al., 1999;
Buchler et al., 1996) indicating that this protein is required for the excretion of a wide
range of conjugated organic anions including bilirubin glucuronides into the bile
(Paulusma and Oude Elferink, 1997; Kartenbeck et al., 1996; Suzuki and Sugiyama,
1998).
MRP2 shows close resemblance to MRP1 in terms of structure and substrate
specificity. Using intact cell and in vitro models it was demonstrated that MRP2
performs an ATP-dependent, primary active transport of the glutathione GS-conjugate
leukotriene C4 and of various glutathione, sulfate, and glucuronide conjugates
(Jedlitschky et al., 1996, 1997). It has also been demonstrated to transport unconjugated
xenobiotics, such as vinblastine and sulfinpyrazone in association with GSH (Evers et
al., 1998, 2000; Van Bladeren, 2000; Glatt, 2000; Ritter, 2000; Paumi et al., 2001). It
has been suggested that MRP2, like MRP1 is capable of transporting GSH, either alone
or together with other substrates. Paulusma et al. (1999) demonstrated a role for MRP2
in the excretion of GSH both in vivo and in vitro. In rats heterozygous for a MRP2
mutation (TR/tr) biliary excretion of GSH was decreased to 63% of controls, and in
MDCKII cells stably expressing MRP2, GSH efflux was more than 10-fold higher than
in parental MDCKII cells.  Competitive inhibition of ATP-dependent DNP-GS transport
in membrane that vesicles isolated from MDCKII-MRP2 cells was observed by high
concentrations of GSH, suggesting that MRP2 mediates low-affinity transport of GSH
(Paulusma et al., 1999). This observation is in accord with the finding that suppression29
of MRP2 levels by antisense in HepG2 cells elevates the intracellular concentration of
GSH two-fold (Koike et al., 1997).
Compared to MRP1, MRP2 has a more limited tissue distribution. In humans
MRP2 is mainly expressed in liver, kidney and small intestine (Kool et al.,1997). MRP2
is found in the canalicular membrane of hepatocytes (Paulusma et al., 1996; Buchler et
al., 1996). In human and rat kidney it is expressed in the apical domain of the proximal
tubule epithelia where it presumably mediates the export of conjugated organic anions
into the urine (Schaub et al., 1999). Studies of rat and rabbit Mrp2 expression in small
intestine showed that Mrp2 is found in the brush border membrane surface of villi
(Mottino et al., 2000; van Aubel et al., 2000). Villi have an absorptive function and thus
Mrp2 could prevent or modulate the passage of certain xenobiotics or their metabolites
from the gut into the portal blood.
Based on its localization and substrate specificity, it is proposed that the
physiological function of MRP2 is the transport of xenobiotics into bile and the lumen
of excretory organs.
1.3.1.3  MRP3
MRP3 (ABCC3) is an organic anion transporter mostly expressed in liver
cholangiocytes, kidney and gut (Kool et al., 1997; Scheffer et al., 2002). In addition,
MRP3 is present in pancreas, adrenal gland and prostate. Within the MRP family MRP3
shares the highest amino acid identity with MRP1 (58%) and MRP2 (49%). Like
MRP1, MRP3 is localized in the basolateral membranes in polarized cells (König et al.,
1999b; Kool et al., 1999b).
While under normal conditions MRP3 expression is hard to detect in
hepatocytes, it is strongly induced under cholestatic conditions in hepatocytes from
MRP2-deficient Dubin–Johnson syndrome patients and in TR(-) rats (Kool et al.,
1999b; König  et al., 1999b; Hirohashi et al., 1998; Ortiz et al., 1999). It has been
suggested that MRP2 and MRP3 expression may be inversely regulated in a coordinated
manner (Stockel et al., 2000). MRP3 mRNA is induced by bilirubin (Ogawa et al.,30
2000).  It has been proposed for human (Kool  et al., 1999b) and rat (Ogawa et al.,
2000) that MRP3 mediates the efflux of organic anions from the hepatocyte into the
blood when secretion into the bile is not sufficient due to reduced MRP2 expression.
Rat Mrp3 has been demonstrated to transport some bile salts in conjugated and
unconjugated form (Hirohashi, 2000); it therefore may also be involved in the
recirculation of bile salts into the blood. Results obtained by Zelcer et al. (2003)
supported the assumption that MRP3 may have a role in the removal of bile acids from
the liver under cholestatic conditions. MRP3 transports both taurocholate and
glycocholate and sulfated bile salts showed to be high-affinity competitive inhibitors of
etoposide glucuronide transport by MRP3 (Zelcer et al., 2003b).
Little is known about additional factors increasing human hepatic MRP3
expression. It has been observed that MRP3 expression was induced in livers of patients
treated with omeprazole and by beta-naphthoflavone in HepG2 cells (Hitzl et al., 2003).
MRP3 is expressed in the endothelial cells of human term placenta tissue, like
MRP1 (St.Pierre et al., 2000). Thus MRP1 and MRP3 in this tissue may serve to
prevent or limit entry of organic anions into the fetal circulation while allowing
excretion of conjugated waste products into the maternal circulation.
MRP3 differs from MRP1 and MRP2 in that it appears to be unable to transport
GSH (Kool  et al. 1999b, Zelcer et al., 2001). This may explain why cells expressing
MRP3 are not resistant to most of the anticancer drugs that are postulated to be
cotransported with GSH by MRP1 and MRP2. Exceptions are the epipodophyllotoxins,
etoposide and teniposide. MRP3-mediated resistance against these drugs does not
require intracellular GSH, and etoposide appears to be transported by MRP3 in
unmodified form (Kool et al., 1999b; Zelcer et al., 2001; Zeng et al., 1999; König  et al.
1999b).
MRP3 is present in cancer cell lines from many tissues but initial studies did not
suggest any association between MRP3 levels and resistance (Kool, 1997). Recently a
strong correlation was found between MRP3 and doxorubicin resistance in lung cancer
lines (Young et al., 1999, 2001). As MRP3 does not cause anthracycline resistance in
transfected cell lines, the clinical significance of this correlation is doubtful.31
1.3.1.4  MRP4 and MRP5
MRP4 and MRP5 are „short“ MRPs that lack the TMD0 N-terminal domain
present in MRP1 (fig. 1.3). They share only 36% sequence identity, even although they
transport similar substrates.
The tissue distribution of MRP4 and MRP5 is not well defined at the moment.
Recent studies suggest that MRP4 is highly expressed in kidney and prostate (Lee et al.,
2000). Subcellular localization of MRP4 is still controversial Lee et al. (2000) analyzed
transfected cells and prostate tissue immunohistochemically to determine  the
subcellular localization of MRP4. They detected MRP4 in the basolateral membrane of
the acinar cells in the prostate. Recently,  van Aubel et al. (2002) reported that MRP4 is
localized in the apical membrane of the proximal tubule of the human kidney. In
contrast to this observation, Lai and Tan (2002) recently localized MRP4 by
immunocytochemistry in the basolateral membrane of polarized MDCKII cells. MRP5
is ubiquitously expressed, with highest levels in skeletal muscle and brain (Kool et al.,
1997; McAleer et al., 1999; Belinsky et al., 1998; Zhang et al., 2000). In polarized
MDCKII cells, MRP5 is localized in the basolateral membrane (Wijnholds et al.,
2000b).
Overexpression of MRP4 and MRP5 has not been detected in drug resistant cell
lines suggesting that their role in ‘classical’ drug resistance is limited (Kool  et al.,
1997, 1999a). They confer a unique drug resistant phenotype transporting cyclic
nucleotides and nucleotide analogs, a class of amphipathic conjugates apparently not
transported by MRP1–3 or 6. The rate of cyclic nucleotide transport by these
transporters is low and the physiological role of this transport remains to be defined.
MRP4 overexpression was demonstrated to confer resistance to the antiretroviral
compound 9-(2-phosphonyl methoxyethyl) adenine (PMEA) and to azidothymidine
monophosphate (AZT-MP) but much less to other nucleoside analogs used in antiviral
therapy (Schuetz et al., 1999). It has been proposed that MRP4 modulates the cellular
response to ganciclovir (GCV) (Adachi et al., 2002). MRP4 transports methotrexate32
(MTX) as well as the physiological folates folic acid (FA) and N(5)-
formyltetrahydrofolic acid (leucovorin)(Chen et al., 2002). It has been shown by Zelcer
et al. (2003a) that bile salts, and cholestatic estrogens are substrates of MRP4,
suggesting an involvement of MRP4 in transport of conjugated steroids and bile acids.
The authors found also that MRP4 is able to transport dehydroepiandrosterone-3-sulfate
(DHEAS), the most abundant circulating steroid in humans, made in the adrenal gland.
Both MRP4 and MRP5 transport cGMP and cAMP, with the difference that
MRP4 has a higher affinity for cAMP and MRP5 for cGMP (Jedlitscky, 2000; Hopper
et al., 2001). cGMP and cAMP are important second messengers activating cellular
signal transduction pathways, and it has been speculated that MRP4 and MRP5 might
play a regulatory role in signal transduction pathways by removing cyclic nucleotides
from the cell. The observation that Silfenadil (Viagra), trequinsin, and zaprinast, which
inhibit the degradation of intracellular cGMP by phosphodiesterases, have been shown
to reduce MRP5-mediated transport (Jedlitscky, 2000) could support this hypothesis.
MRP4 and 5 could possibly mediate resistance to nucleobases and nucleoside
analogs that are used in anticancer and antiretroviral therapies. Both MRP4 and MRP5-
overexpressing cells showed low-level resistance against 6-mercaptopurine (6MP) and
6-thioguanine (TG). MRP4 and MRP5 may be involved in thiopurine resistance and
pharmacokinetics in leukemia patients (Wielinga et al., 2002). No human disease has
been associated with alterations in MRP5, and the Mrp5 (-/-) mice have no obvious
phenotype (Wijnholds et al., 2000b).
1.3.1.5  MRP6
Human MRP6 is mainly expressed in liver and kidney (196, 294, 295). In the rat
liver Mrp6 is predominantly found in the basolateral membrane of hepatocytes (Madon
et al., 2000; Borst , Oude Elferink , 2002). In contrast to some other MRPs, the
expression level of Mrp6 is stable. The overexpression of MRP6 in drug resistant cells
is associated with co-amplification of MRP1. This may be related to the localization of
the two genes closed on the same chromosome (Kool et al., 1999a).33
The substrate specificity of MRP6 is still not well defined, little is known about
its functional characteristics and its potential role in drug resistance. The first substrate
identified by vesicular transport experiments was BQ-123, an anionic cyclopentapeptide
antagonist of the endothelin A receptor (Madon et al., 2000). It has recently been shown
that expression of MRP6 is also associated with MgATP-dependent transport of
glutathione S-conjugates like leukotriene C4, S-(2,4-dinitrophenyl) glutathione and N-
ethylmaleimide S-glutathione (NEM-GS) but not glucuronide conjugates (Ilias et al.,
2001). Additionally, MRP6-transfected cells showed low levels of resistance to natural
product drugs like etoposide, teniposide, doxorubicin, and daunorubicin (Belinsky et al.,
2002).
The 3’ end of the MRP6 gene is amplified in leukemic cells resistant to
epirubicin (Longhurst et al., 1996; O’Neill et al., 1998; Kuss et al., 1998). Resistance
was initially thought to be due to a new resistance protein, called ARA, the
anthracycline resistance gene. Subsequent work has shown, however, that the epirubicin
resistance of cell lines with ARA gene amplification can be explained by the
coamplification of the MRP1 gene together with the MRP6 gene (Kool et al., 1999a;
Belinsky and  Kruh, 1999).
The physiological role of MRP6 remains to be clarified. Mutations of the MRP6
gene are associated with pseudoxanthoma elasticum (PXE), a heritable connective
tissue disorder characterized by calcification of elastic fibers in skin, arteries, and retina.
How mutations in  MRP6 are associated with this disease is still unclear (Ringpfeil  et
al., 2000).
1.4  Work preceding this thesis
1.4.1  Characterization of truncation mutants of MRP1
MDR1 Pgp (ABCB1) and MRP1 (ABCC1) share a similar core structure,
containing a tandem repeat of transmembrane domains (TMDs) and cytoplasmic ATP-34
binding cassette (ABC) regions. However, MRP1 and several homologs form a
subfamily of ABC-transporters, characterized by a triple membrane-bound domain
structure. These include an MDR1-like core region, containing two ABC units and two
membrane-bound domains (TMD1 and –2), and an N-terminal polypeptide region of
about 280 amino acids, forming a cytoplasmic loop and a membrane bound domain (L0
and TMD0, respectively). To examine the role of the N-terminal regions in the function
of MRP1, Bàkos et al. analyzed MRP1 variants (containing either the MDR-like core
alone, called ∆ MRP1, or the core plus linker L0 called L0∆ MRP1). It was examined
whether the mutants were able to transport substrates of MRP1 by vesicle uptake
experiments with the MRP1 substrates leukotriene C4 (LTC4) and N-ethylmaleimide
glutathione (NEM-GS). It was found in these studies that the mutant ∆ MRP1 was
inactive. By indirect immunofluorescence it was demonstrated that the expression of
∆ MRP1 in polarized MDCKII was restricted to an intracellular compartment.
Unexpectedly, a truncated MRP1 mutant lacking only the entire first transmembrane
domain, TMD0, but still containing L0 (L0∆ MRP1) behaved like wild-type MRP1 in
vesicle uptake and nucleotide trapping experiments. L0∆ MRP1 was properly routed to
the lateral plasma membrane in MDCKII cells where it transported DNP-GS and
daunorubicin (fig. 1.5). These results suggested that the loop L0 forms a functional
domain that is sufficient and essential for MRP1-mediated transport activity and routing
to the lateral membrane in polarized cells. Interestingly, L0 is conserved among all the
members of the MRP family identified to date. It was speculated that L0 could be
required for substrate recognition, for lateral routing and/or for proper folding of the
molecule. The N-terminal region TMD0 did not demonstrate any apparent function,
which is unexpected as this domain is present in other MRP homologs (MRP2, MRP3,
MRP6 and MRP7). Although this region shows a low overall amino acid identity
among these proteins, it is structurally conserved in evolution.35
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Fig. 1. 5. Schematic representation of truncated mutants of MRP1 and their characterization
To investigate whether fusing L0 to the N-terminus of MDR1 would make
MDR1 Pgp an organic anion transporter, Bàkos et al., (2000a) constructed chimeric
MRP1-MDR1 mutants. All MRP1-MDR1 chimeric proteins expressed in Sf9 cells
preserved the transport characteristics of wild type MDR1 and were routed to the apical
membrane in MDCKII cells.
1.4.2  Identification of an amphipathic helix within the loop L0
If the L0 loop is co-expressed with ∆ MRP1 in Sf9 cells, transport activity is restored
(Bàkos et al., 2000a). In vitro experiments demonstrated that a significant amount of the
L0 protein was associated with the membrane fraction in vesicles. Only by washing the
membranes with urea or Triton-X100 the association between L0 and the membrane was
disrupted. Secondary structure predictions indicated the presence of a conserved
amphipathic helix in all currently known MRP homologues. Analysis of this region
demonstrated that it is conserved among MRP1-9 and in the yeast cadmium resistance
factor Ycf1 (fig. 1.6), an orthologue of human MRP1 (Tommasini et al., 1996)36
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Fig. 1.6. Sequence alignments and predicted secondary structure of L0 regions corresponding to aa 198-
241 in MRP1.
A. Sequence alignments of the L0 loop of MRP1-6 and of the yeast homologue YCF1.
B. Computer-predicted distribution of the residues in the helix in MRP1-6. Hydrophobic residues are
signed in red, hydrophilic in black.
The hydrophobic (in red, fig. 1.6 panel B) and hydrophilic (in black, fig. 1.6 panel
B) amino acids are distributed on opposite sides of the helix in all MRP proteins. The
amphipathic helix may produce hydrophobic interactions with the lipid bilayer or with
hydrophobic regions of other membrane proteins.37
2  AIMS OF THIS THESIS
In previous studies by Bàkos et al., (1998) on the N-terminal domain of MRP1 it
has been shown that the MDR1-like core of MRP1, called ∆ MRP1, is inactive and
localized in an intracellular compartment in Madin-Darby Canine Kidney (MDCKII)
cells. In baculovirus infected Sf9 cells transport function could be restored by co-
expressing the full N-terminal TMD0L0 region together with ∆ MRP1. It was also found
that extending the core with the N-terminal linker L0 in the absence of the TMD0 region
resulted in an active transporter that was properly routed to the plasma membrane in
MDCKII cells. To extend these previous results, this thesis describes the isolation and
characterization of MDCKII cell lines stably expressing various MRP1 variants. The
final aim was to investigate the role of the intracellular loop L0 in basolateral routing
and to characterize the role of this domain in MRP1-mediated drug transport in
polarized MDCKII cells.
Based on computer secondary structure predictions of the loop L0 a conserved
amphipathic α -helix was identified in MRP1.  An MRP1 variant was generated in
which this region was deleted. An MDCKII-derived cell line stably expressing this
mutant was established and the transport and routing characteristics of the mutant were
investigated.
To investigate whether L0 could rescue the transport activity and lateral routing
of the intracellularly localized ∆ MRP1, MDCKII cells were co-transfected with L0 and
∆ MRP1. By confocal laser microscopy (CLSM) the localization of L0 in these cells was
studied.
To investigate the N-terminal TMD0L0  region of MRP1 in further detail,
MDCKII-derived cell lines stably expressing TMD0L0 alone or together with ∆ MRP1
were isolated. By various experimental strategies like immunofluorescence-, Western
blotting-, deglycosylation-, vectorial transport-, co-immunoprecipitation- and surface
biotinylation experiments, the characteristics of MRP variants in these cell lines were
studied.38
To determine whether L0 of MRP2 (an apically localized homolog of MRP1)
could substitute for L0  of MRP1, a chimeric TMD0L0  construct was engineered
consisting of the TMD0 of MRP1 and L0 of MRP2. MDCKII–derived clones stably
expressing the chimeric construct were established. In addition the construct was
expressed in MDCKII-∆ MRP2 cells. In these cells, the chimeric protein was studied by
immunofluorescence and deglysosylation experiments39
3  MATERIALS AND METHODS
3.1  Materials
3.1.1  Plasmids
3.1.1.1  Bacterial expression-vectors
Plasmid Insert Reference
pGEM
 -7Zf(Promega,
Madison, WI)
TMD0(MRP1)L0(MRP2)
chimeric construct
this thesis
3.1.1.2  Eucaryotic expression-vectors
Plasmid Insert Reference
pCMV-neo MRP1∆ (223-232) cDNA cloned by Dr. R.
Evers as described in Bàkos
et al., 2000
pBabe-puro-CMV L0 fragment Bàkos et al., 2000
pCMV-neo TMD0L0 fragment Bàkos et al., 1998
pBabe-puro-CMV TMDo(MRP1)Lo(MRP2)
chimeric construct
this thesis40
3.1.2  Antibodies
3.1.2.1   First antibodies
Antibody Specificity Isotype Provenience
MAb
MRPr1
MRP1, internal epitope
G
238SDLWSLNKE
247
Rat
IgG2a
Dr. R. J. Scheper (Free
University Hospital, Amsterdam,
The Netherlands).
MAb
MRPm6
MRP1, internal epitope
P
1511SDLLQQRGL
1520
Mouse
IgG1
Dr. R. J. Scheper (Free
University Hospital, Amsterdam,
The Netherlands).
Mab
QCRL3
MRP1,conformational
epitope aa 617-932
Mouse
IgG2a
ALEXIS Biochemicals
Deutschland (Grünberg, D)
MAb
M2I-4
MRP2, internal epitope Mouse
IgG1
Dr. R. J. Scheper (Free
University Hospital, Amsterdam,
The Netherlands).
3.1.2.2  Secondary antibodies
Antibody Developed in Provenience
Anti- mouse IgG Peroxidase
conjugate
goat Sigma (Saint-Louis,
Missouri, USA
Anti- mouse IgG Peroxidase
conjugate
goat Zymed laboratories (San
Francisco, CA, USA)
Anti- mouse IgG FITC conjugate sheep Roche Molecular
Biochemicals, (Mannheim,
Germany)41
Anti- rat IgG Peroxidase
conjugate
goat Zymed laboratories (San
Francisco, CA, USA)
Anti- rat IgG FITC conjugate goat Molecular Probes
(Eugene, OR, USA)
3.1.3  Primers
Tos 1
5´AACGGATCCGTGCCCGCCGCCGCCCGCGCCACCGGC3´
Tos2
5´GAATGAAGCTATGGATGATGGATTATTTGATGACTCGTGGATG
GTTTTCCGAGAACAGGGGTGAGCGATCTGA3´
Tos3
5´TCAGATCGCTCACCCCTGTTCTCGGAAACCATCCACGAG
TCATCAAATAATCCATCATCCATAGCTTCATTC3´
Tos 4
5´ATCGGATCCTTACTGCTGGGAGCTCTTCTCCTGCCGTCTCTG3´42
3.1.4  E. Coli Competent cells
Strain Genotype
DH5α supE44, delta lacU169 (phi 80 lacZ delta  M15), hsdR17,
recA1, endA1, gyrA96, thi-1, relA1
Transformed bacteria were incubated over-night at 37°C and 200 rpm in LB
medium with 100µg/ml ampicillin. Bacteria were stored at –80°C in 50% LB medium
and 50% glycerin.
3.1.5  Cell lines and media
Cell line Provenience
MDCKI Madin Darby canine kidney type II (MDCKII) epithelial
cells
Phoenix HEK293T human embryonic kidney cell line
Cells were cultured at 37°C and 5% CO2. MDCKII was cultured in DMEM
medium (Gibco BRL, Life Technologies, Paisley, PA) containing 2mM L-glutamine,
100 U/ml penicillin, 100 mg/ml streptomycin and 10% of heat inactivated (30 min
56°C) FCS. Cells were subcultured each 3-4 days by incubation with trypsine (15-30
min, 37 °C) after washing with PBS. Phoenix cells were cultured in ISCOVES
Dulbecco modified medium (Gibco BRL, Life Technologies, Paisley, PA)43
supplemented as described for DMEM. They were subcultured each 3-4 days by
incubation with trypsine (1 min, 37 °C).
To be stored cells were trypsinized and resuspended DMEM medium (0,5
ml/aliquot). An equal amount of freezing medium (60% DMEM, 20% fetal calf serum
and 20% DMSO) was added slowly to avoid osmotic shock and to minimize the heating
that occurs when DMSO is added to the aqueous solution. Cells were stored for 24 hour
at –80°C before being transferred in liquid nitrogen.
3.1.6  Solutions and buffers
DNA-gel sample buffer Ficoll
SDS
EDTA pH 8
Tris-Cl pH 8
orange G
25%
0.5%
5 mM
20 mM
0.8%
PBS (1x) NaCl
KCl
Na2 HPO4
KH2 PO4
137 mM
2,7 mM
4,3 mM
1,4 mM
TE (1x) Tris-HCl pH 7,4
EDTA
10 mM
1 mM
TAE (1x) Tris-Acetat
EDTA
40 mM
1 mM
DNA-running buffer TAE
Ethidium bromide
1x
0,5 mg/l44
Ligase Mix (10x) Tris-HCl pH 7,4
MgCl2
DTT
0,5 M
0,1 M
0,1 M
PBS C/M PBS
CaCl2
MgCl2
1x
1 mM
0,5 mM
HBSS (10x) KCl
KH2PO4
MgCl2. 6H2O
MgSO4. 7H2O
NaCl
Na2HPO4
HEPES
Glucose
NaHCO3
0,05 M
4 mM
5 mM
4 mM
1,3 M
0,3 M
0,1M
0,05 M
4,2 mM
Lysis buffer KCl
MgCl2
Tris-HCl pH 7,4
SDS
Leupeptin
Pepstatin
Aprotinin
10 mM
1,5 mM
10 mM
2%
1 µg/ml
1 µg/ml
1 µg/ml
SDS sample buffer (2x) SDS
Tris HCl pH 6,8
Glycerin
4%
0,1M
13%45
mercapto-ethanol
Bromophenol blue
0,6%
0,6%
SDS running buffer SDS
Tris
glycine
0,15%
0,05 M
0,2 M
Transfer buffer Tris
glycine
methanol
0,025 M
0,2 M
20%
ECL soulution sodium luminol
H2O2
Tris-HCl pH 8,6
1,25 mM
9,3%
0,1 M
3.1.7  General materials and chemicals
Basic chemicals were from Roth (Karlsruhe, Germany), Merck & Co. Inc (USA)
and Sigma-Aldrich. (Saint-Louis, Missouri, USA). Restriction enzymes as well as
further enzymes for molecular biology are from New England BioLabs and MBI
Fermentas Molecular Biology, (Heidelberg, Germany). Protein molecular ladders were
from Bio-Rad (Hercules, CA, USA) and Gibco BRL Life Technology (Paisley PA).
Double well plates for immunohistochemistry and transport experiments were
Transwell
TM 3414 (Costar) plates. Other plastic materials for cell culture were from
Greiner (Sigma-Aldrich, Saint-Louis, Missouri, USA), Corning/Costar (Myriad
Industries, San Diego, CA), Becton Dickinson (Franklin Lakes, NJ) or Schleicher &
Schuell (Traben Trarbach, Germany). Radioactive inulin, daunorubicin and CDNB were
from Amersham Pharmacia Biothec (Buckinghamshire, England)46
3.2  Molecular biological methods
3.2.1  Polymerase chain reaction
Specific DNA fragments were amplified by PCR. The polymerase chain reaction
was conduced in a total volume of 50 µl containing 10 mM dNTPs, 50 mM MgSO4, 10
pmol/µl primers, 200 ng DNA template, 1-2 U Pfx polymerase (Gibco BRL, Life
Technologies, Paisley PA), and 5 µl 10x Pfx buffer provided from the manufacturer.
After initial DNA denaturation (94 °C for 5 min) 25 cycles were performed, consisting
of 1 min at 94 (denaturation step), 60°C for 1 min (annealing step), 78°C for 1 min
(elongation step). At the end cycles were followed by an incubation of 5 min at 78 °C to
allow complete elongation of all DNA products. PCR products were isolated by
agarose-gel electrophoresis size fractionation, and fragments were purified with a
JETSORB Gel Kit (Genomed, Bad Oeynhausen, Germany).
3.2.2  Enzymatic treatments of DNA
3.2.2.1  Enzymatic digestion with restriction-nucleases
0,5 µg DNA was digested by 1-10 U restriction enzymes in the reaction buffer
suggested by the manufacturer (New England BioLabs, MBI Fermentas Molecular
Biology, Heidelberg, Germany) at at 37°C for 1 hour, as indicated by the manufacturer.
2.2.2.2  Calf Intestinal Alkaline Phosphatase (CIP) reaction
Alkaline phosphatase catalyses the removal of 5' phosphate residues from DNA
to prevent self-ligation. DNA was suspended in the reaction buffer provided by the47
manufacturer and 0,5-1U CIP (Roche Molecular Biochemicals, Mannheim, Germany)
were added. The reaction was incubated 15 minutes at 37°C.
3.2.2.2  Ligation of DNA fragments
For ligating DNA fragments into plasmid vectors 4 to 1 fold molar excess of
insert fragment to vector was used. Twenty units T4-DNA-ligase (New England
BioLabs) and 1 µl of 10 mM ATP were added to 10 µl of 1x ligase Mix ( Tris-HCl pH
7,4 0,5 M, MgCl2 0,1 M, DTT 0,1M). The reaction was incubated for 12-16 hours at
16°C.
3.2.3  Separation of DNA fragments by agarose gel electrophoresis
Agarose gel electrophoresis was used to size fractionate DNA molecules. 0,7 to
1% agarose is suspended in 1X TAE containing 1 µg/ml ethidium bromide for
visualization of nucleic acids. Ethidium bromide is an intercalating dye, which binds to
the DNA and fluoresces under UV light. 0,7 to 1% agarose gels can separate DNA
fragments from 0,5-6 Kb in size. Electrophoresis occurred in TEA buffer. DNA was
visualized under UV light at 366 nm.
3.2.4  Cloning of MRP1 and MRP1/MRP2 variants in expression
vectors
For expression of the MRP1 variants MRP1∆ (223-232) and TMD0L0 in kidney-
derived MDCKII cells, cDNAs were inserted as blunt-end fragments into the retroviral
vector pCMV-neo (Bàkos et al., 1998, 2000).
The L0 fragmente was cloned in the pBabe-puro-CMV vector. This vector was
generated by cloning the blunt-ended HindIII fragment (Bàkos et al., 2000).48
TMD0(MRP1)L0(MRP2) was generated by overlap PCR as described in 3.6.1,
and the fragments were verified by sequence analysis. The amplified overlap product
was digested with Bam HI and was inserted by ligation into the Bam HI digested
cloning vector pGEM
 -7Zf, codifying for resistance to ampicillin, (Promega, Madison,
WI).
Competent E. Coli  cells from the strain DH5α  were transformed with the
plasmid. The plasmidic DNA was isolated from a positive clone, purified in agarose gel
and extracted in significant quantity by midi preparation. From pGEM
 -7Zf the
construct was cloned into the BamHI digested site of the pBabe-puro-CMV vector.
Plasmids are shown in 2.5.
3.2.5  Transformation of competent cells
E. Coli DH5α  cells were transformed with ligation mixtures in order to select
and amplify plasmids containing recombinant DNA fragments.
3.2.5.1  Preparation of competent cells (DH5αααα )
Solution 1 100 mM RbCl2 , 50 mM MnCl2 , 30 mM KaAc, 10 mM CaCl2 ,
13% Glycerin (v/v) pH 5,8
Solution 2 10 mM MOPS (pH 7,0), 10 mM RbCl2 , 75 mM CaCl2 , 13 %
Glycerin (v/v) pH 7,0
A single colony of E. Coli was inoculated in 5 ml of LB broth without ampicillin
and incubated over night at 37°C. The culture was grown to OD600 = 0,5. Cells were
centrifuged and the pellet was suspended in 200 ml solution 1 and incubated on ice for 2
hours. After the incubation the cells were collected by centrifugation for 10 min, 4°C,49
2000 rpm and resuspended in 15 ml of solution 2. Hundred µl cell aliquots were frozen
in liquid nitrogen and stored at –80°C.
3.2.5.2  Transformation of competent cells
Ten µg of DNA were added to a 100 µl aliquot of competent bacteria thawed on
ice. To allow the DNA to enter the cells, they were incubated on ice for 30 min. The
bacteria were heat-shocked for 90 seconds at 42°C and cooled on ice for 30 seconds.
Subsequently 1 ml of LB medium was added and the cells were incubated at 37°C for
60 min. A 100 µl aliquot was plated on an LB Amp agar plate (100µg/ml ampicillin)
and incubated over night at 37°C.
3.2.6  Isolation of plasmid DNA from E. Coli
3.2.6.1  Mini preparation
Buffer P1 50 mM Tris-Cl pH 8, 10mM EDTA, 100g/ml RNase A
Buffer P2 200mM NaOH, 1% SDS
Buffer P3 3M potassium acetate, pH 5,5
Single cultures of transformed bacteria were amplified over night in 5 ml LB
containing 100µg/ml ampicillin. The bacterial pellet was collected by centrifugation at
3000 rpm for 10 min. The pellet was resuspended in 100 µl buffer P1 and incubated on
ice 200 µl of buffer P2 was added. After incubating for 5 minutes at 4 °C, 100 µl of
buffer P3 were added. Lysates were centrifuged at 13000 rpm for 5 minutes at room50
temperature and the supernatant was added to 800 µl of ethanol (100%). DNA was
precipitated by centrifugation at 13000 rpm for 10 minutes at room temperature. 300 µl
of cold ethanol (70%) were added to the pellet and it was centrifuged at 13000 rpm for 5
minutes at room temperature. After drying of the pellet, it was resuspended in water (30
u/µl).
3.2.6.2  Midi preparation
Higher amounts of plasmid DNA were obtained from amplification of 100 ml of
bacterial cultures using a JETSTAR Plasmid Kit (Genomed, Bad Oeynhausen,
Germany) following the protocol provided by the manufacturer.
3.2.6.3  Determination of DNA concentration
By samples without significant contamination, the absorption of ultra-violet
(UV) light by the ring structure of purines and pyrimidines can be used to measure the
amount of DNA. A DNA sample was tested in a spectrophotometer for absorbance at
wavelengths of 260 nm and 280 nm, where OD260 measures nucleic acids and OD280
proteins. The concentration can be calculated based on an OD of 1 at 260 nm
corresponding to 50 µg/ml for double stranded DNA. The purity of the DNA solution
can be estimated using the ratio of OD readings at 260nm and 280nm. Pure preparations
of DNA have an OD260/OD280 ratio of 1,8.51
3.3  Cell culture methods
3.3.1  Transfection of Phoenix packaging cells and collection of the
viral supernatant
24 hours before transfection cells were subcultured 1:7 in 10 cm diameter tissue
culture plates. Approximately 3 hours before transfection medium was replaced. Cells
were transfected with Calcium Phosphate using a kit from Gibco BRL, (Gibco BRL
Life Technologies, Paisley PA).
After over night incubation, medium was changed. After 24 hours the medium
containing the virus released by the Phoenix cells was removed, centrifuged at 1500
rpm for 5 min, divided into 1 ml aliquots and stored at –80°C. Cells were washed in
cold (4°C) PBS and scraped from the plate. After washing two times with PBS the cells
were resuspended in lysis buffer containing SDS. Protein lysates were analyzed by
Western blotting.
3.3.2  Retroviral transduction of MDCKII cells
MDCKII cells grown to confluence in monolayer were subcultured 1:10 in a
T25 flask. The next day 1 ml of viral supernatant, 1,15 ml DMEM and 10 µl DOTAP
(Roche Molecular Biochemicals, Mannheim, Germany) were added. After 3-4 hours of
incubation at 37°C, 1,5 ml DMEM were added. The day after transduction medium was
replaced. The next day cells were diluted 1:8, 1:16, 1:32, 1:64, 1:128 in 10 cm Ø
diameter tissue culture plates. Cells were selected in medium containing 3 µg/ml
puromycin for 4-6 days or 800 µg/ml gentamycin (G-418) for 7 days. After selection
positive clones were isolated and identified by Western blotting.52
3.3.3  Analysis of MDCKII monolayers by immunofluorescence
For identification of the proteins by immunocytochemistry cells were grown on
microporous polycarbonate filters (3µm pore size, 24,5 mm diameter) at a density of
4*10
5 cells/well to confluence (for 3 days). Medium was changed every day, and was
replaced 1 hour before starting the experiment.
Cells were fixed in 3% formaldehyde in PBS for 10 min at RT. To allow
entrance of the monoclonal antibodies, cells were permeabilized with 0,1% Triton X-
100 in PBS for 5 min. Cells were incubated for 2 hours at RT with the first mAb diluted
1:100 in 3% BSA in PBS; subsequently with FITC labeled secondary antibody diluted
1:50 in 3% BSA in PBS (anti-rat for MRPr1, anti mouse for MRPm6, QCRL3 and
M2I4) for 1 hour in the dark. After each step cells were washed two times 5 min with
PBS C/M. Filters were placed on microscope slides. A drop Vectashield Mounting
Medium (H-1000) (VECTORlabs, Burlingame, CA) containing 1µg/ml propidium
iodide was added. Propidium iodide is a membrane-impermeant dye that stains by
intercalating into nucleic acid molecules. Monolayers were viewed by confocal laser
scanning microscopy.
3.3.4  Transport essays with MDCKII cells
3.3.4.1  Transport DNP-GS by MDCKII monolayers
Cells were seeded at a density of 16*10
5/well on double well plates (Costar) and
grown to confluence (for 3 days). Medium was changed every day and was replaced 1
hour before starting the experiment. Export of  radioactive dinitro-phenyl-glutathione
([
14C]DNP-GS) from cells was determined by incubating cells with 1-chloro-2,4-
dinitro[
14C]benzene (10 Ci/mol) (CDNB) (Amersham Pharmacia Biothec,
Buckinghamshire, England). [
14C]CDNB was dissolved in dimethyl sulfoxide to a
concentration of 10 mM and diluted in HBSS (Hanks buffered saline solution) to a53
concentration of 2 µM just before the start of the experiment. 2 ml of medium
containing [
14C]CDNB were applied to both the apical and basal compartment of the
monolayer and 200 µl aliquots were taken at various time points (t = 1, 3, 6, 12, 20
min). Incubations were done at RT. Samples were immediately extracted with 200 µl of
ethyl acetate and centrifuged for 2 min at 12000 rpm. Radioactivity in 160 µl samples of
the hydrophobic phase was determined by liquid scintillation counting. The amount of
radioactivity was corrected for the decrease in volume of the culture medium. To
determine [
14C]DNP-GS accumulated in the cell monolayer, cells were washed with
cold PBS, filters were cut from the plate and counted directly in liquid scintillation
fluid.
3.3.4.2  Transport of [
3H]Daunorubicin by MDCKII monolayers
Cells were seeded on microporous polycarbonate membrane filters and grown to
confluence (see above). One hour before starting the experiment monolayers were
preincubated with DMEM containing 0,1 µM PSC833 to inhibit endogenous canine
MDR1 Pgp (Evers et al., 1998). The experiment was started (t = 0) by replacing the
medium at either the apical or the basal side of the cell monolayer with 2 ml of
complete medium containing 2 µM of [
3H]Daunorubicin (4 µCi/ml) (Amersham
Pharmacia Biothech Buckinghamshire, England), [
14C]-labeled inulin (0.025 µCi/ml,
4.2 µM) (Amersham Pharmacia Biothec, Buckinghamshire, England), and 0,1 µM
PSC833. The cells were incubated at 37°C in 5% CO2 and 50 µl aliquots were taken
from each compartment at various time points (t = 1, 2, 3, 4 h). Radioactivity was
measured as the fraction of total radioactivity added at the beginning of the experiment.
The paracellular flux was monitored by the appearance of inulin [
14C]carboxylic acid in
the opposite compartment. Radioactivity was determined by liquid scintillation
counting.54
3.3.5  Cell surface biotinylation essays
3.3.5.1  Selective cell surface biotinylation – detection by confocal
laser scanning microscopy
MDCKII cells were seeded and grown to confluence as described in 2.3.3. The
monolayers were treated at either the apical or the basolateral compartment with 10mM
sodium periodate (NaIO4) (freshly prepared) for 30 min at 4°C allowing oxidation of
sugar residues. After washing two times for 5 min with PBS C/M, surface proteins were
labeled with 2 mM EZ-Link
TM Biotin Hydrazide (Pierce, Rockford, IL) dissolved in
sodium acetate pH 5,5 (freshly prepared) for 30 min at 4°C. After washing, cells were
fixed with formaldehyde (3% in PBS) for 10 min at RT, washed and labeled for 15 min
in the dark with Fluorescein Avidin DCS (VECTOR labs, Burlingame, CA). Filters
were placed on microscope slides and mounted as described above.
3.3.5.2  Cell surface biotinylation – precipitation of biotinylated
proteins
MDCKII cells were seeded at a density of 16*10
5 in 6 well plates and grown to
confluence for 3 days. The cell surface was incubated with 10mM sodium periodate
(NaIO4) (freshly prepared) for 15 min at 4°C to allow oxidation. After washing two
times for 5 min with PBS C/M surface proteins were labeled with 2 mM EZ-Link
TM
Biotin Hydrazide (Pierce, Rockford, IL) in sodium acetate, pH 5,5 (fresh) for 30 min at
4°C. UltraLink Immobilized Monomeric Avidin (Pierce, Rockford, IL) were pretreated
2 mM biotin in PBS for 10 min, washed twice with 0,1 M glycine pH2,8 and two times
with PBS. After biotinylation of the cells, plates were scraped with 200 µl of lysis
buffer (50mM Tris-Cl pH8, 150mM NaCl, 1% NP 40, pepstatin, aprotinin, leupeptin
each 1µg/ml). Insoluble material was pelleted spinning the lysates at 13000 rpm. A 20µl55
sample was taken for Western blot analysis. The volume of the supernatant was brought
to 950 µl with lysis buffer and 50 µl of the pretreated beads were added. After over-
night incubation at 4°C with end-over-end rotation beads were collected by brief
centrifugation for 30 seconds at 14000g. After washing the beads, bound material was
eluted using 2 mM biotin PBS and analyzed by Western blot.
3.3.6  Membrane isolation from MDCKII cells
MDCKII cells were n grown to confluence, washed in PBS (37°C), scraped and
centrifuged at 1200 rpm for 5 min. After washing the pellet 2 times with PBS, it was
resuspended in hypotonic lysis buffer (20mM Tris-Hepes pH 7,4, 1 mM PMSF,
aprotinin, pepstatin, leupeptin, each 1µg/ml) and left on ice for 30 min The pellet was
homogenized in Dounce homogenizer and centrifuged at 2500 rpm, 5 min, 4°C. Cell
lysate was loaded on sucrose cushion (38% sucrose in 20 mM Tris-Hepes pH 7,4, 1 mM
EDTA) and centrifuged in ultracentrifuge at 30000 rpm for 2h at 4°C. The membrane
containing band was removed, diluted in TS buffer (10 mMTris-Cl pH 7,4, 250 mM
sucrose) and centrifuged at 30000 rpm, for 30 min, at 4°C. The pellet was resuspended
in PBS containing protease inhibitors.
3.4  Protein analysis
3.4.1  Cell lysates
After trypsinization cells were pelleted by centrifugation at 2000 rpm for 5 min
and washed two times with PBS. Pellet was resuspended in lysis buffer containing 1mM
PMSF (phenyl methyl sulfonyl fluoride ), 2% SDS and aprotinin, pepstatin, leupeptin
(each 1µg/ml) and mechanically disrupted by sonification.56
3.4.2  Determination of protein concentration
The protein concentration in cell lysates was determined using the Roti-Quant
(Roth, Karlsruhe, Germany) kit based on the Bradford method. The colorimetric method
is based on the proportional binding of Coomassie to proteins. Coomassie absorbs at
595 nm. The protein concentration of a test sample is determined by comparison to that
of a series of protein standards (BSA) known to reproducibly exhibit a linear
absorbance profile in this assay. Eight hundred µl of the essay reagent and 200 µl of
water were mixed to each of four standard solutions of BSA (0, 2, 8, 12, 20 µg/ml) and
to 2µl of protein sample (cell lysate). After incubation at room temperature for 5-30
min, the absorbance of each sample at 595 nm was measured.
3.4.3  SDS-polyacrylamide gel electrophoresis (SDS-PAGE)
Stacking gel Polyacrylamide
Tris-HCl pH 6,8
APS
SDS
TEMED
5%
0,06 M
3 mM
0,1%
0,03%
Resolving gel Polyacrylamide
Tris-HCl pH 8,8
APS
SDS
TEMED
7,5/11%
0,375 M
3 mM
0,1%
0,06%57
SDS-PAGE permits separation of proteins under denaturing conditions. When
an electric current is applied to the gel, protein migration is determined by their
molecular weight. Cell lysates were diluted in sample buffer 1:1 and loaded onto a
polyacrylamide gel. The separating gel contained 7,5 or 11% polyacrylamide and the
stacking gel contained 5% polyacrylamide. Gels were electrophoresed at 150 Volt for 1
hour in SDS-running buffer.
3.4.4  Western blot analysis
Ponceau S Ponceau
acetic acid
0,5% (w/v)
1% (v/v)
blocking milk BSA
milkpowder
Tween 20
PBS
10% (w/v)
10%(w/v)
0,05% (v/v)
1x
The proteins separated by SDS-PAGE were transferred to a solid membrane for
Western blot analysis. To obtain protein transfer an electric current is applied to the gel
so that the separated proteins move through the gel and onto the membrane in the same
pattern as they separate on the SDS-PAGE. After electrophoresis the pre-wet (in
transfer buffer) fiber pads and filter paper, the SDS gel and the nitrocellulose membrane
were assembled in the transfer cassette. Transfer was conduced over-night, at 4°C, 0,1
Ampere/gel. After transfer the membrane was stained with Ponceau S for 5 minutes to
visualize protein bands. The blotted nitrocellulose membrane (Schleicher & Schuell,
Traben Trarbach, Germany) was blocked in freshly prepared blocking milk for 1 hour at
room temperature with constant agitation. The first antibody was diluted 1:500 in
blocking milk and nitrocellulose membrane was placed in the primary antibody solution
and incubated for 2 hours at room temperature. The membrane was washed 3 times for58
10 min at RT in blocking milk before incubating membrane in the secondary antibody
coupled with horseradish peroxidase for 1 hour (dilution 1:1000). The membrane was
washed as described and one time with PBS for 10 min at RT. Proteins were detected by
enhanced chemiluminescence (ECL). The washed membrane was incubated with 0,125
ml luminol solution per cm
2 with 1% (v/v) enhancer solution (5*10
-4 M p-hydroxy
coumaric acid in DMSO). The peroxidase oxidates luminol in presence of hydrogen
peroxide. Following the reaction, luminol reaches an exited state and decays to the
ground state via the emission of light that is detected by placing the blot in contact with
an X-ray film (Hyperfilm, Amersham Pharmacia Biothec, Buckinghamshire, England).
3.4.5  Co-immunoprecipitation
MDCKII cells were grown to confluency, scraped and resuspended in lysis
buffer (150 mM NaCl, 1mM EDTA, 50 mM Tris-Cl pH 7, 1% NP40, 10% glycerol, 1
mM PMSF, aprotinin, pepstatin, leupeptin, each 1µg/ml) on ice. Lysates were
centrifuged at 2500 rpm at 4°C to pellet insoluble material After storage of the
supernatant on ice for 30 min, it was centrifuged at 14000 rpm for 10 min at 4°C. A
sample (10% of the total amount) was taken for Western blot analysis. Cell lysates were
diluted in a detergent solution (0,1% CHAPS, 10 mM Tris-Cl, 50 mM NaCl). ∆ MRP1
was immunoprecipitated using Dynabeads Protein A (Dynal Biothech, Oslo, Norway)
with captured mAb QCRL3, following the procedure described by the package insert.
Precipitated proteins were detected by Western blot.59
3.4.6  Enzymatic deglycosylation of glycoproteins
3.4.6.1  Deglycosylation with Tunicamycin
MDCKII cells were cultured in medium containing 3µg/ml tunicamycin for 0,
12, 25 or 40 hours. After the incubation time cell lysates were prepared as described in
2.4.1 and analyzed by Western blot.
3.4.6.2  Deglycosylation with N-glycosidase F
Membranes from MDCKII cells isolated as described in 2.3.6, were treated with
N-glycosidase F (Roche Molecular Biochemicals, Mannheim, Germany) as indicated in
the kit protocol. Samples were not incubated at 95 °C. Proteins were detected by
Western blot.
3.4.6.3  Deglycosylation with Endoglycosdase H
Cell lysates prepared as described 2.4.1 in were treated with Endo H from New
England BioLabs, following the procedure indicated in the kit protocol. Proteins were
detected by Western blot.60
3.5  Plasmids
3.5.1  pGEM
 -7Zf
Picture taken from the Promega catalog, www.promega.com61
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4  RESULTS
4.1  Monoclonal antibodies specifically recognizing human MRP1
In this thesis three different monoclonal antibodies (mAbs) were used for the
detection of MRP1 and its mutant forms by Western blotting and immunofluorescence.
MAb MRPr1 recognizes an internal epitope between amino acids (aa) 238 and 247
within the loop L0. MAb MRPm6 recognizes an internal epitope between aa 1511 and
1520 at the very C-terminal part of the protein (Flens et al., 1994; Hipfner et al., 1998).
MAb QCRL3Q recognizes a conformation-dependent internal epitope (aa 617-932) of
human MRP1 (Hipfner  et al., 1994, 1999).
TMD2 TMD1
H2N
COOH
in
out
NBD1 NBD2 L0
238GSDLWSLNKE247
mAb MRPr1
1511PSDLLQQRGL1520
mAb MRPm6
TMD0
aa 617-932
mAb QCRL3
Fig. 4.1. Schematic representation of MRP1.
The epitopes recognized by the antibodies used in this thesis are indicated. Asn residues19, 23 and 1006
are N-glycosylated. Sugar residues are represented by the branched structures.63
4.2  Characterization of the MDCKII-MRP1∆(223-232) cell line
4.2.1  Expression of MRP1∆(223-232) in MDCKII polarized cells
In order to analyze whether the amphipathic α -helix in the N-terminal linker L0
(fig. 1.6) was essential for routing and/or function, a 10-aminoacid deletion ∆ (223-232)
was constructedin full length MRP1. The deletion is shown in fig. 4.2 (panel A). The
construct was kindly provided by R. Evers
 An MDCKII cell line stably expressing MRP1∆ (223-232) was generated by
retroviral transduction. For expression MRP1∆ (223-232) cDNA was inserted as blunt-
end fragment into the retroviral vector pCMV-neo (Bàkos et al., 2000).
In fig. 4.2 (panel B), a Western blot with cell lysates from MDCKII-
MRP1∆ (223-232) cells is shown. To estimate the expression level of MRP1∆ (223-232),
4 and 20 µg of protein were size fractionated, and compared with the same amounts of
protein from lysates from MDCKII-MRP1 and wild-type MDCKII cells. The
MRP1∆ (223-232) protein was efficiently produced and detected in similar quantities as
the positive control MRP1 (lanes 3 and 4 versus lanes 5 and 6). No signal was detected
in the non-transfected cells (lanes 1 and 2).
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Fig 4.2 The mutation ∆ (223-232) in MRP1.
A.The construct MRP1∆ (223-232) lacks the 10-amino acid long sequence between Trp223 and Tyr232
contained into the predicted amphypathic alpha helix .
 B. Western blot analysis of lysates from parental MDCKII, MDCKII-MRP1and MDCKII-MRP1∆ (223-
232) cells. Four and 20 µg of protein were size-fractionated. The blot was incubated with mAb MRPr1
In lysates from MDCKII-MRP1∆ (223-232) cells two bands were detected: a
band with an apparent molecular weight of 190, consistent with the molecular weight of
wild-type MRP1, and an additional band of about 170 kDa, which corresponds to the
molecular weight of non-glycosylated MRP1 (fig. 4.2, panel B, lanes 2 and 3 versus
lanes 5 and 6 and see below).
4.2.2  Determination of the glycosylation state of MRP1∆(223-232)
in MDCKII cells
Many membrane proteins are covalently linked to oligosaccharide chains. The
carbohydrate units are linked to an asparagine residue by N-glycosidic bonds or to65
serine and threonine residues by O-glycosidic bonds. The asparagine residue must be
part of an Asn-X-Ser of Asn-X-Thr motif and has to be sterically accessible to the
transferase. In MRP1 the following three asparagine residues are known to be
glycosylated: Asn 19, Asn 23 and Asn 1006 (Hipfner et al., 1997).
As shown in fig. 4.3 (panel A) the synthesis of the glycosidic chain starts from
dolichol phosphate, a long phosphorylated complex lipid. Active monosaccharide
derivatives of UDP, GDP and dolichol phosphate are added sequentially to dolichol
phosphate by transferases until a 14-residue block is built.
The activated oligosaccharide core, consisting of two N-acetylglucosamine, nine
mannose and three glucose residues, is attached to the nascent protein at the luminal
side of the endoplasmic reticulum. Subsequent modifications will occur in the Golgi
apparatus resulting in the typical core of N-linked oligosaccharide chains. The core
itself will undergo further changes reaching its final sugar composition. Tunicamycin is
an antibiotic inhibitor of N-glycosylation. It is an analog of UDP-N-acetylglucosamine,
which competes for the binding of dolichol phosphate at the very first step of the
synthesis.
A
Dolichol P P
protein
Dolichol P P (Glc)3  (Man)9  (GlcNAc)2  
protein   Asn  (GlcNAc)2   (Man)9  (Glc)3 66
Dolichol P
UDP-Glc-NAc
UMP
Dolichol P P Glc-NAc
Tunicamycin
B
Fig. 4.3. Core glycosylation of proteins at Asn residues.
A. Mechanism of action of tunicamycin: nascent proteins are N-glycosylated by transfer of an activated
oligosaccharide to an asparagine residue.
B. The first step of the synthesis of the activated oligosaccharides: the reaction of dolichol phosphate with
UDP-N-acetylglucosamine. Tunicamycin is a hydrophobic analog of UDP- N-acetylglucosamine, which
prevents glycosylation by acting as a competitive inhibitor.
To determine whether the MRP1∆ (223-232) protein was glycosylated, cell
monolayers were treated with tunicamycin for 12, 25 and 40 hours. Fig. 4.4 shows a
Western blot with lysates of MDCKII-MRP1 and MDCKII-MRP1∆ (223-232) cells
prepared after treatment: a protein with an apparent molecular weight of 170 kDA was
detected by Western blot analysis (lanes 2-3 and 6-8). The size of this protein
corresponds to the molecular weight of non-glycosylated MRP1.
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Fig. 4.4. Deglycosylation of MRP1 and ∆ MRP1.
Western blot with lysates from MDCKII-MRP1 and MDCKII-MRP1∆ (223-232) cells, treated with
tunicamycin (3 µg/ml) for 0, 12, 25 and 40 hours.67
4.2.3  Subcellular localization of MRP1∆(223-232) in MDCKII
monolayers
By confocal laser scanning microscopy (CLSM), it was investigated if the
deletion of the α -helix was affecting basolateral routing of the protein. Fig. 4.5 shows
the immunolocalization by CLSM of the mutant MRP1∆ 223-323 in MDCKII-derived
monolayers. The upper part shows a top view of the monolayer (X/Y section), whereas
the lower part shows a vertical (X/Z) laser scan perpendicular to the monolayer. Like
wild-type MRP1, MRP1∆ 223-323 is routed to the lateral plasma membrane. The 10
amino acid deletion in this mutant did not affect the sorting of this mutant indicating
that these residues are not required for the lateral routing of MRP1.
Fig. 4.5. Immunolocalization of MRP1∆ (223-232) in MDCKII monolayers.
MRP1∆ 223-323 was detected by indirect immunofluorescence with mAb MRPr1 (green signal). Nucleic
acids were counterstained with propidium iodide (red signal).68
4.2.4  Characterization of the transport activity of MRP1∆(223-232)
in MDCKII cells
4.2.4.1   [
14C]DNP–GS transport in MDCKII monolayers: experimental
procedure
It has been shown before that dinitro-phenyl-glutathione (DNP-GS) is
transported into inside-out membrane vesicles isolated from MRP1 overexpressing cells
(Jedlitschky et al., 1994; Müller et al., 1994). Subsequently, it was demonstrated that
DNP-GS is a substrate for MRP1 in intact cells. This finding was useful for the
development of a sensitive assay to measure the rate of MRP1-mediated transport from
polarized cells overproducing MRP1 in the basolateral membrane (Evers et al., 1996).
The general principle of this system is shown in fig. 4.6: Madin-Darby Canine Kidney
(MDCKII) cells grow in so called double-well plates on a porous membrane where they
form a tight monolayer. The porous membrane separates the culture plate into two
compartments, an apical and a basolateral compartment. The cells form the physical
barrier between both compartments (panel A). Typically non-metabolized drugs are
added to either the apical or basolateral compartment and the amount of drug
accumulating in the opposite compartment is measured. For transport experiments with
chloro-dinitrobenzene (CDNB), the substrate is added to both compartments.
To measure transport of DNP-GS, the culture medium is replaced by a buffer
containing radioactive [
14C]CDNB at t = 0. This hydrophobic compound rapidly enters
the cell by diffusion. In the cytoplasm, it is metabolized to [
14C]dinitro-phenyl-
glutathione (DNP-GS) by glutathione S-transferases (GST) (panel B). [
14C]DNP-GS a
hydrophilic compound, which can only leave the cell by the mediation of an active
transporter (panel C). Therefore, the amount of [
14C]DNP-GS detected in the buffer has
been actively transported out of the cell. As [
14C]CDNB is also present in the medium
both [
14C]DNP-GS and [
14C]CDNB would contribute to the total radioactivity measured.
To measure only [
14C]DNP-GS, the two substances are separated by extraction with
ethyl acetate. [
14C]DNP-GS remains in the aqueous phase, while [
14C]CDNB partitions
into the hydrophobic phase. Samples of medium are taken from the apical and the69
basolateral compartment at fixed time-points. The time-dependent accumulation of
[
14C]DNP-GS in both compartments is determined.
GS - H H - CL
Cl
NO2
[14C] chloro-dinitro-benzene [14C] dinitro-phenyl-glutathione
SG
NO2
++
NO2 NO2
GST
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basal
monolayer of polarized
MDCKII cells
porouse membrane
A
B
C
porouse membrane
[14C] DNP-GS [14C] CDNB
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MDCKII cells
basal compartment
[14C] CDNB [14C] DNP-GS
GST
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Fig. 4.6. Transport of DNP-GS in MDCKII monolayers.
A. MDCKII monolayers are grown on a double-well plate. Support is a porous membrane.
B. Radioactive [
14C] CDNB is added instead of the culture medium. It is metabolized to DNP-GS by
cellular glutathione S-transferases (GST).
C. The exit of radioactive [
14C] DNP-GS is mediated by an active transporter.
4.2.4.2  Transport of [
14C]DNP–GS in MDCKII-MRP1∆(223-232)
monolayers
Fig. 4.7 shows the transport activity of MRP1(∆ 223-323) in MDCKII
monolayers. [
14C]DNP-GS transport was performed as described above (fig. 4.6) and
the activities of MRP1 and MRP1(∆ 223-323) were compared. Wild-type MDCKII cells
were used as a negative control. Samples were taken at t = 0, 1, 3, 6, 12 and 20 minutes70
and extracted with ethyl acetate. The experiments were performed twice in duplicate.
The results clearly indicate that the deletion of amino acids 223-232 completely
abolished transport activity.
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Fig. 4.7. Transport of DNP-GS by MDCKII derived monolayers.
Cells were incubated in the presence of [
14C]CDNB at room temperature and the amount of DNP-GS
exported into the medium was determined. Squares indicate transport into the basolateral compartment,
circles the transport to the apical compartment. Samples were taken at 0, 1, 3, 6 and 20 min.
4.3  Co-expression of the cytoplasmic loop L0 with ∆MRP1 in MDCKII
cells
To investigate the role of the cytoplasmic loop L0  in more detail, L0  was
expressed together with the inactive C-terminal core of MRP1, ∆ MRP1 (amino acids
280-1531). These two truncated mutants of MRP1 are shown schematically in fig. 4.8.
The construct L0 was cloned into the pBabe-puro-CMV vector, and introduced into
MDCKII cells by retroviral transduction as described in 4.3.1.71
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mAb MRPm6 mAb QCRL3
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Fig. 4.8. Expression of L0 and DMRP1 in MDCKII cells.
Schematic representation of the truncated mutants of MRP1. The intracellular loop L0, containing the
epitope for mAb MRPr1, and ∆ MRP1, containing the epitopes for the monoclonal antibodies QCRL3 and
MRPm6.
4.3.1  Generation of stable MDCKII cell lines expressing L0  and
∆MRP1
Retroviruses are an efficient method to stably deliver DNA to a wide range of
mammalian cell types. They integrate with high efficiency mediating stable expression.
The retroviral vectors are transiently transfected into a helper packaging cell line
(Phoenix cells) that produces all viral proteins required for the packaging of the
retroviral DNA except the packaging signal, which is contained in the retroviral vector.
Currently available retroviral vectors for dividing mammalian cells are based on
the Moloney murine leukemia virus (MMULV). Packaging cell lines are either
ecotropic (capable of delivering genes to dividing murine or rat cells) or amphotropic
(capable of delivering genes to dividing cells of most mammalian species, including
human). The Phoenix cell lines are based on the HEK293T cell line (a human
embryonic kidney cell line), which can be efficiently transfected by either calcium
phosphate-mediated transfection or liposome-based transfection protocols. Fifty
percentage or higher of cells can be transiently transfected. Virus producing cells
continuously generate retroviral vector particles, which are released into the growth
medium.72
To isolate MDCKII cells stably expressing the L0 construct I first transfected
Phoenix packaging cells using the calcium phosphate technique with the pBabe-puro-
CMV-L0 vector. The supernatant from the virus producing Phoenix cells was used to
retrovirally-transduce MDCKII-∆ MRP1 cells. To generate a cell line derived from one
single positive cell, the density of the transduced cellular pool was reduced by serial
dilution. Cells were selected with puromycin to isolate clones as the L0 pBabe-puro-
CMV vector contains the puromycin resistance gene. Isolated single resistant clones
were cultured and analyzed by Western blot analysis.
Calcium phosphate transfection
of Phoenix-MMULV vector cells
Phoenix cells release retrovirus 
containing the transfected DNA in medium
Virus is collected
Retroviral transduction of MDCKII
monolayers
Progressive dilutions of the transduced
pool and selection with 3 µg/ml  Puromycin
Identification of positive clones by Western Blot analysis
1:2 1:8 1:16 1:4 . . . 
Fig. 4.9. Generation of stable MDCKII cell lines expressing TMD (MRP1)L0(MRP2) by retroviral
transduction.
Transfection of Phoenix packaging cells, collection of the retroviral supernatant, transduction of MDCKII
and MDCKII-∆ MRP1 and selection with puromycin of positive clones.73
4.3.2  Immunolocalization of L0 in MDCKII-L0+∆MRP1 monolayers
It was found by Bàkos et al. (1998) that the presence of L0 is necessary to route
the mutant L0∆ MRP1 to the basolateral plasma membrane. I therefore wanted to
investigate whether the peptide L0 is able to reach the plasma membrane if co-produced
in MDCKII-∆ MRP1 cells.
Figure 4.10 shows the localization of the loop L0  co-expressed with ∆ MRP1 in
MDCKII monolayers by CLSM. The isolated clone of MDCKII-∆ MRP1 cells
expressing the loop L0 was part of a pool of puromycin resistant cells. Clear basolateral
localization of L0 was detected in small groups of cells. Since only a small percentage of
cells of the pool showed staining with mAb MRPr1 it was impossible to isolate single
clones. Consequentially I could not perform Western blot analysis or transport
experiments. L0 was not detectable in wild-type MDCKII cells retrovirally-transduced
with the L0 construct. Probably the peptide is not stable and rapidly degraded.
Fig. 4.10. Immunolocalization of L0 in MDCKII monolayers by confocal laser scanning microscopy.
The upper picture represents a top view of the monolayer (X/Y), the lower pictures are vertical sections of
the monolayers (X/Z). Nuclei were counterstained with propidium iodide (red signal). L0 was detected
with mAb MRPr1 (green signal).74
4.4  Characterization of the N-terminal region of MRP1 (TMD0L0) in
MDCKII polarized cells
4.4.1  Isolation of stable MDCKII clones expressing TMD0L0
As it was not possible to isolate a cell line stably expressing the loop L0 alone, I
selected MDCKII cells producing the TMD0L0  (amino acids 1-281) polypeptide.
TMD0L0 consists of the first transmembrane domain of MRP1, TMD0, extended with
the intracellular loop L0. Cell lysates of single clones were analyzed by Western blotting
(fig. 4.11, Panel B). TMD0L0 appeared as a smear of bands with a molecular weight
ranging from 40-70 kDa. This might be due to glycosylation as the protein contains two
of the three glycosylation sites of MRP1 (Asn 19 and Asn 23, and see fig. 4.1). To
better estimate the amounts of TMD0L0 produced by the different clones, 4 and 20 µg of
protein were size fractionated. For further characterization of the protein in MDCKII
cells, I chose the clone showing the highest expression level: clone #25 was selected for
further experiments.
H2N
TMDo
Lo
A
238GSDLWSLNKE247
mAb MRPr175
Fig. 4.11 Expression of TMD0L0 in MDCKII cells.
A. Schematic representation  of TMD0L0. Glycosylation sites and the epitope of mAb MRPr1 are shown.
B. Detection of TMD0L0 by Western blotting. Lysates from independent clones of MDCKII-TMD0L0
cells were analyzed. Proteins were size-fractionated in a 7,5% acrylamyde gel. To compare the relative
expression levels, 4 and 20 µg of protein were loaded. The blot was incubated with mAb MRPr1.
4.4.2  Immunolocalization of TMD0L0 in MDCKII monolayers
Figure 4.12 shows the detection with mAb MRPr1 of TMD0L0 in MDCKII
monolayers by CLSM. A high amount of intracellular staining was observed, but in
several vertical sections some apparent lateral localization was detected. In the X/Y
section a clear dark rim is visible around the nucleus in some cells, suggesting that in
these cells TMD0L0 is localized in the plasma membrane. The vertical sections (X/Z)
confirm this: besides intracellular staining in the majority of the cells, staining of the
lateral membrane was observed in some cells (e.g. X/Z section 1).76
Fig. 4.12. Immunolocalization of TMD0L0  in MDCKII monolayers by confocal laser scanning
microscopy.
 The upper picture represents a top view of the monolayer (X/Y), the lower pictures are vertical sections
of the monolayers (X/Z 1-3). Nuclei were counterstained with propidium iodide (red signal), TMD0L0
was  detected with mAb MRPr1 (green signal).
4.4.3  Cell surface biotinylation of MDCKII-TMD0L0 monolayers
4.4.3.1  The principle of cell surface biotinylation
Biotin is a vitamin with a molecular weight of 244 Dalton present in blood and
in tissue. Gitlin et al. found in 1987 that biotin binds with very high affinity to avidin, a
basic glycoprotein found in the egg white and tissue of birds, reptiles and amphibia.
This protein is a tetramer with a total molecular weight of 67000 Dalton. The avidin-
biotin interaction is the strongest non-covalent biological interaction known between
protein and ligand, and it is only disrupted under drastic conditions.
I used biotin hydrazide for incorporation of biotin into the carbohydrate groups
of glycoproteins proteins after their oxidation with sodium periodate. Oxidation
generates aldehyde groups that can react spontaneously with the hydrazide as shown in77
fig. 4.13. This way several biotin molecules can be coupled to a protein, enabling the
biotinylated protein to bind more than one molecule of avidin.
Fig. 4.13. Biotinylation of glycoproteins.
Biotin hydrazide binds covalently to the carbohydrates of glycoproteins after the oxidation to aldehydes.
Avidin reacts selectively with biotinylated proteins: a protein can be conjugated with several molecules of
biotin.
As the plasma membrane is not permeable to biotin, glycoproteins localized in
the apical or basolateral plasma membrane can be biotinylated selectively in cells grown
in monolayer by adding biotin hydrazide to either the apical or the basolateral
compartment (fig. 4.14).
The biotinylated proteins could be detected by confocal laser scanning
microscopy after binding to fluorescently labeled avidin (fig. 4.14, panel A).
Alternatively, biotinylated proteins can be precipitated by incubation of cell lysates with
agarose-bound avidin and detected by Western blot analysis (fig. 4.14, panel B).78
Fig. 4.14. Selective cell surface biotinylation of a monolayer of polarized cells.
A. Biotinylated surface proteins can be detected by reaction with fluorescent avidin. The upper picture
shows selective biotinylation of apical proteins in a MDCKII monolayer, the lower shows basolateral
biotinylation.
B. Biotinylated proteins can be isolated from a whole lysate by precipitation if avidin is fixed to an inert
solid support.
4.4.3.2  Precipitation of biotinylated proteins and identification of
TMD0L0 by Western blot analysis
To investigate further whether part of TMD0L0 was localized in the lateral
membrane (fig. 4.12), I carried out a cell surface biotinylation with MDCKII-TMD0L0
cells. MDCKII-MRP1 cells were used as a positive control in these experiments. Fig.
4.15, lane 5 shows the precipitated amount of MRP1 protein. The signal in lane 4
(containing the non-precipitated fraction) was weak, indicating that only a small amount
of MRP1 was non-biotinylated. Precipitated protein from MDCKII-TMD0L0 lysates was
size fractionated in lane 2. After biotinylation, a significant amount of TMD0L0 was
binding to avidin, indicating that part of the molecules is located in the plasma79
membrane. The relative high amount of unprecipitated TMD0L0 (Lane 1) reflects the
high quantity of cytoplasmic TMD0L0 also seen by immunolocalization.
Fig. 4.15. Cell surface biotinylation of MDCKII- TMD0L0 and MDCKII-MRP1 monolayers.
The surface of the monolayer was biotinylated by treatment with biotin hydrazide after oxidation with
sodium periodate. After biotinylation the monolayers were lysed and the biotinylated proteins were
precipitated with immobilized avidin beads. The precipitated proteins were eluted with D-biotin and then
separated by size fractionation in a 7,5% polyacrylamide gel under denaturing conditions. MRP1 and
TMD0L0 were detected with mAb MRPr1.
Lanes marked with p represent the precipitated fraction; i indicates the input (10% of the lysate before
precipitation). As control, after precipitation 10% of the supernatant, containing non-precipitated,
cytoplasmic protein was size fractionated (lanes marked with K).
4.5  Characterization of the N-terminal region of MRP1 (TMD0L0) in
MDCKII-∆MRP1 polarized cells
4.5.1  Generation of an MDCKII cell line stably expressing TMD0L0
and ∆MRP1
It was tried to investigate if the L0 peptide was able to rescue ∆ MRP1 to the
plasma membrane(Bàkos et al. 2000), but technically it was not possible to isolate a
MDCKII-∆ MRP1 clone stably expressing L0. As an alternative approach, I therefore80
transduced MDCKII-∆ MRP1 cells with the retroviral vector pCMV-neo-TMD0L0. After
selection with G-418, several clones were isolated stably co-expressing TMD0L0 and
∆ MRP1. A schematic representation of the constructs is shown in figure 4.16 (panel A).
Together the two mutant peptides make-up a full-length MRP1 molecule.
Panels B and C show the Western blot analysis of lysates from MDCKII-
TMD0L0+∆ MRP1 cells. On the blots, the MRP1 fragments expressed in one cell
(MDCKII-∆ MRP1+TMD0L0  cells) are compared to cells expressing ∆ MRP1 or
TMD0L0 alone (MDCKII-∆ MRP1 and MDCKII-TMD0L0 cells, respectively). TMD0L0
detected with mAb MRPr1 in lysates from MDCKII-∆ MRP1+ TMD0L0 cells (panel B,
lane 1) looks similar to that in lysates from MDCKII-TMD0L0 cells (lane 3). As a
negative control lysates from MDCKII-∆ MRP1 cells were size fractionated (Lane 2).
No signal was detected in these cells with mAb MRPr1. As a positive control, lysates
from MDCKII-MRP1 monolayers were analyzed (lane 4). In panel C, proteins were
detected using mAb MRPm6. In lane 1 the signal of ∆ MRP1 in MDCKII-
∆ MRP1+TMD0L0 cells is shown, while ∆ MRP1 in MDCKII-∆ MRP1 lysates is shown
in lane 2. There is a clear difference between the signals detected in the two cell lines:
in the MDCKII-∆ MRP1+TMD0L0 cells an additional band running at a somewhat
higher apparent molecular weight is detectable that is absent in MDCKII-∆ MRP1 cells.
As a negative control lysates from MDCKII-TMD0L0 cells were size fractionated in lane
3; as a positive control, lysates from MDCKII-MRP1 monolayers were analyzed in lane
5.
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Fig. 4.16. Co-expression of TMD0L0 and ∆ MRP1 in MDCKII cells.
A. Schematic representation of the truncated mutants of MRP1, TMD0L0 and ∆ MRP1. TMD0L0 contains
the epitope for mAb MRPr1, and ∆ MRP1 contains the epitopes for mAbs MRPm6 and QCRL3.
B, C. Western blot analysis of lysates from MDCKII-TMD0L0+∆ MRP1, MDCKII-∆ MRP1, MDCKII-
TMD0L0  and MDCKII-MRP1 cells. Twenty µg of protein were size fractionated in a 7,5%
polyacrylamide gel under denaturing conditions. After electroblotting one blot was incubated with mAb
MRPr1 (panel B); a parallel blot was incubated with mAb MRPm6 (panel C).
4.5.2  Glycosylation state of TMD0L0  and ∆MRP1 in MDCKII-
TMD0L0+∆MRP1 monolayers
In order to investigate the glycosylation state of the truncation mutants of MRP1
in MDCKII-TMD0L0+∆ MRP1 cells, membranes were isolated from these cells and
incubated with N-glycosidase F. N-glycosidase F digests virtually any N-linked sugars
from glycoproteins (Tarentino and Plummer, 1994). Sugars are removed by enzymatic
cleavage of the bond between the first N-acetylglucosamine and the asparagine residue
of the protein (Figure 4.17, panel A).82
Panels B and C in figure 4.17 show a Western blot of membrane fractions of
MDCKII-TMD0L0+∆ MRP1 cells. Like in fig. 4.16 (panel C), the signal for ∆ MRP1 in
MDCKII-TMD0L0+∆ MRP1 lysates consisted of two bands. The proteins had an
apparent molecular weight of about 150 kDa and 170 kDa, respectively. In contrast, the
signal for ∆ MRP1 in MDCKII-∆ MRP1 lysates consisted of only one band with an
apparent molecular weight of 150 kDa. In order to investigate whether the additional
170 kDa band detected in MDCKII-TMD0L0+∆ MRP1 lysates is due to glycosylation,
membrane extracts from these cells were treated with N Glycosidase F. As positive
control I used membranes isolated from MDCKII-MRP1 cells. In figure 4.17 (Panel B)
lysates from MDCKII-MRP1 and MDCKII-∆ MRP1+ TMD0L0 cells treated (lanes 2 and
4) and untreated (lanes 1 and 3) with N-glycosidase F were size fractionated. The
disappearance of the signal at 170 kDa in lane 4, indicates that part of the ∆ MRP1
molecules is glycosylated in the presence of TMD0L0.
In panel C deglycosylation of proteins in membrane extracts from MDCKII-
TMD0L0 and MDCKII-TMD0L0+∆ MRP1 cells is shown. TMD0L0 was detected with
mAb MRPr1. The results for the two cell lines are similar: after deglycosylation only
one polypeptide with an apparent molecular weight of about 22 kDa was detected.
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Fig. 4.17. Deglycosylation of TMD0L0 and ∆ MRP1 in MDCKII- TMD0L0+∆ MRP1 monolayers.
A. Mechanism of action of N-glycosidase F. N-glycans are digested from asparagine residues.
B, C. Detection by Western blotting of MRP1, TMD0L0+∆ MRP1 and TMD0L0 after treatment with N-
glycosidase. MDCKII-MRP1, MDCKII- TMD0L0  and MDCKII-TMD0L0 +∆ MRP1 membranes were
incubated with N-glycosidase F for 1h at 37°C (lanes marked with “+”). As a negative control membranes
were incubated under the same conditions without enzyme (lanes marked with  “-”).
Panel B. MRP1 and TMD0L0+∆ MRP1 were size-fractionated in a denaturing
7,5% polyacrylamide gel after incubation with (+) or without (-) N-glycosidase F.
Western blots were incubated with mAb MRPm6. Panel C. Membrane fractions from
MDCKII- TMD0L0  and MDCKII- TMD0L0+∆ MRP1 were size-fractionated in a
denaturing 11% polyacrylamide gel after treatment with (lanes 2 and 4) or without
(lanes 1 and 3) N-glycosidase F. The Western blots were incubated with mAb MRPr1.84
4.5.3  Immunolocalization of TMD0L0  and of ∆MRP1 in MDCKII-
TMD0L0+∆MRP1 and MDCKII-∆MRP1 monolayers
To verify if TMD0L0 affects the subcellular localization of ∆ MRP1 in MDCKII
cells co-expressing these two fragments, I analyzed MDCKII- TMD0L0+∆ MRP1
monolayers by confocal laser scanning microscopy.
Panel A in fig. 4.18 shows the immunolocalization of ∆ MRP1 in MDCKII cells
when TMD0L0 is absent. The picture shows that ∆ MRP1 is not localized in the plasma
membrane and that its detection is restricted to the cytoplasm, in accord with what has
been shown before by Bàkos et al. (1998).
Panel B shows the immunolocalization of TMD0L0 and ∆ MRP1 in MDCKII-
TMD0L0+∆ MRP1 cells. The results for TMD0L0 confirm what was shown in figures
4.12 and 4.15 for MDCKII-TMD0L0 cells; the mutant is partially localized in the plasma
membrane. TMD0L0 was detected by indirect immunofluorescence using mAb MRPr1.
In contrast to what is shown in panel A, in MDCKII-TMD0L0+∆ MRP1 cells
∆ MRP1 is routed to the plasma membrane due to the presence of TMD0L0. Like in
panel A, ∆ MRP1 was detected with the mAb QCRL3.85
Fig. 4.18. Immunolocalization of TMD0L0 and ∆ MRP1 in MDCKII- TMD0L0+∆ MRP1 monolayers.
A. Immunolocalization by confocal laser scanning microscopy of ∆ MRP1 in MDCKII monolayers.
∆ MRP1 was detected by indirect immunofluorescence with mAb QCRL3.
B. Immunolocalization of TMD0L0 and of ∆ MRP1 in MDCKII monolayers co-expressing both proteins.
Proteins were detected by indirect immunofluorescence with mAb MRPr1, (left side of panel B) which
epitope is in the region L0 between aa 238-247, and with mAb QCRL3 (right site panel B).
In both panels antibody signals are represented in green and nucleic acids are counterstained with
propidium iodide, giving a red signal In each picture a top view (X/Y) of the monolayers and vertical X/Z
sections are shown.86
4.5.4  Transport properties of TMD0L0+∆MRP1 in MDCKII
monolayers.
Since part of ∆ MRP1 was demonstrated to be routed to the lateral plasma
membrane in MDCKII-TMD0L0+∆ MRP1 monolayers, I investigated whether co-
expression of TMD0L0 with ∆ MRP1 resulted in reconstitution of transport activity. I
compared the transport of the typical MRP1 substrates DNP-GS and daunorubicin by
MDCKII-TMD0L0+∆ MRP1 monolayers to transport observed in MDCKII-∆ MRP1 and
MDCKII-TMD0L0 monolayers. As positive control the transport by MDCKII-MRP1
monolayers was determined, as negative control transport by wild-type MDCKII
monolayers.
In fig. 4.19 (panel A), I measured the amount of [
14C]DNP-GS transported to the
apical and to basolateral side in the various cell lines. Neither in MDCKII-TMD0L0 nor
in MDCKII-∆ MRP1 monolayers transport activity was detectable. In contrast,
basolateral transport of DNP-GS by MDCKII-TMD0L0+∆ MRP1 (TL19 in the figure)
monolayers was comparable to the amount transported by MDCKII-MRP1 cells.
Panel B shows the amount of [
3H]-Daunorubicin transported to the apical and to
the basolateral side by the same cell lines as in panel A. While MDCKII-TMD0L0 and
MDCKII-∆ MRP1 cells did not show transport, MDCKII-TMD0L0+∆ MRP1 monolayers
demonstrated a significantly increased basolateral transport of daunorubicin.87
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Fig. 4.19. Transport properties of TMD0L0+∆ MRP1 in MDCKII monolayers.88
A. Transport of DNP-GS by MDCKII, MDCKII-MRP1, MDCKII-TMD0L0  and MDCKII-
TMD0L0+∆ MRP1 (TL19) cells. Cells grown on filters for three days were incubated with 2 µM
[
14C]CDNB in the apical and in the basal compartment. This compound enters the cells by diffusion;
intracellularly it is conjugated to glutathione by the mediation of glutathione-S-transferases. MRP1 is able
to transport DNP-GS out of the cells. Samples were taken from both compartments at t = 0, 1, 3, 6, 12 and
20 minutes. Squares, transport to the basal compartment; circles, transport to the apical compartment. The
experiments were performed in duplicate and repeated twice.
B. Transport of [
3H]-daunorubicin by MDCKII, MDCKII-MRP1 and TMD0L0+MDCKII-∆ MRP1 cells.
Transport is expressed as the percentage of total radioactivity added at the beginning of the experiment at
t = 0. Samples from both compartments were taken at t= 0, 1, 2, 3, 4h. PSC 833 (0,1µM) was present in
both compartments to inhibit endogenous MDR1 Pgp (Bàkos et al., 1998).
4.5.5  Demonstration of the interaction between TMD0L0  and
∆MRP1
4.5.5.1  Immunoprecipitation and co-immunoprecipitation
The principle of immunoprecipitation exploits the possibility to use an antibody
to separate an antigen recognized by the antibody from a mixture of proteins in solution,
for example a cell lysate. In general the antibody-antigen complex itself is soluble, so
that a direct separation after complex formation is not possible. To separate the complex
by precipitation, the antibody is fixed to a solid support (e.g. beads coated with protein
A or G), containing immunoglobulin-binding proteins with high affinity to the antibody.
After coupling of the monoclonal antibody to the beads, they are incubated with
the cell lysate in the presence of detergent. An incubation period follows, to allow the
recognition of the antigen by the antibody resulting in the formation of an antigen-
antibody complex. The resulting complex may also include proteins interacting with the
antigen recognized by the antibody.
The beads I used for our experiments were paramagnetic, so that the separation
of the bound proteins from the non-bound fraction could be done by magnetic
separation. After separation from the solution, the precipitated protein complexes are
disrupted under denaturing conditions and analyzed by SDS-Page.89
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Fig. 4.20. Scheme representing the mechanism of immunoprecipitation.
A monoclonal antibody is fixed to a solid support through protein A or G. The antibody-coated beads are
incubated with the solution containing the antigen (ovals in figure). The antibody recognizes the antigen
and an insoluble complex is formed. The complex includes also an antigen-binding protein (triangles in
figure). After separation from the solution, the proteins present in the complex can be identified by SDS-
page.90
4.5.5.2  Co-immunoprecipitation of TMD0L0 and ∆MRP1 in MDCKII-
TMD0L0+∆MRP1 cells
The data demonstrating the glycosylation of ∆ MRP1 in MDCKII-
TMD0L0+∆ MRP1 cells (fig. 4.17), the MRP1-like transport activity (fig. 4.19, panel B)
and the partial basolateral localization of ∆ MRP1 (fig. 4.18, panel A) in these cells
suggest that the TMD0L0 and ∆ MRP1 molecules interact with each other. In order to
verify this hypothesis, I performed an immunoprecipitation. Lysates of MDCKII-
TMD0L0+∆ MRP1 cells were incubated with mAb QCRL3 coupled to paramagnetic
beads. The precipitated proteins were identified by Western blot analysis as shown in
figure 4.21. As control I used MDCKII-TMD0L0  cells. Eluted proteins were size
fractionated in lanes 1 and 3 (lanes marked with IP). Ten percent of the incubation
mixture was removed from the cell lysate before precipitation, and size fractionated as
an input control (lanes 2 and 4 (input)). After Western blotting, TMD0L0 was detected
with mAb MRPr1. TMD0L0 was co-immunoprecipitated from lysates made from cells
co-expressing ∆ MRP1 and TMD0L0 (lane 1). That this interaction was specific was
suggested by the finding that no TMD0L0 protein was immunoprecipitated from cells
expressing TMD0L0 alone (lane 3).
Fig. 4.21. Co-immunoprecipitation of TMD0L0 with ∆ MRP1 from MDCKII-TMD0L0+∆ MRP1 cell lysates.
For precipitation mAb QCRL3 was used. Detection by Western Blot analysis.91
Precipitated proteins were eluted from Dynal beads with 2x SDS sample buffer and size fractionated in a
7,5% denaturing polyacrylamide gel (lanes labeled with IP). The Western blot was incubated with mAb
MRPr1. As control, 10% of the input lysates was taken before precipitation and size fractionated. (Lanes
signed with input).
4.6  Characterization of the chimeric construct TMD0(MRP1)L0(MRP2)
in MDCKII cells
4.6.1  Generation of TMD0(MRP1)L0(MRP2) by overlap PCR
A possible explanation for the results described above is that the TMD0L0
fragment of MRP1 contains a basolateral routing signal To investigate whether the
routing signal was contained in L0, I generated a chimeric cDNA consisting of TMD0 of
MRP1 and L0 of MRP2. The chimeric cDNA encoding TMD0(MRP1)Lo(MRP2) was
cloned using overlap PCR.
For the PCR overlap technique complementary oligodeoxyribonucleotide (oligo)
primers and the polymerase chain reaction are used to generate two DNA fragments
with overlapping ends at their 3’ and 5’ ends, respectively. These fragments are
combined in a subsequent PCR reaction in which the overlapping ends of the two
fragments anneal to each other, allowing the 3’ overlap of each strand to serve as a
primer for the 3’ extension of the complementary strand. The resulting fusion product is
amplified further by PCR using the 5’ primer from the original upstream fragment
(Oligo 1 in fig. 4.22, panel A) and the 3’ primer from the original downstream fragment
2 (Oligo 4 in fig. 4.22, panel A). Specific mutations in the nucleotide sequence can be
introduced by incorporating nucleotide changes into the overlapping oligo primers.
For the PCR amplification of the cDNA fragment coding for T1 MRP1 cDNA
was used as template. Primer 1, flanking the 5’ -end contained a Bam HI restriction site.
The primer flanking the 3’ end of T1 (primer 2) included in its sequence the initial bases
of the sequence of L0 (MRP2), followed by TMD0 sequence of MRP1. The upstream
primer for the generation of fragment L2 contained at its 5’ end nucleotides encoding92
TMD0 of MRP1 followed by sequence encoding L0 of the MRP2 cDNA. The 3’ Primer 4
contained a Bam HI restriction site. MRP2 cDNA was used as the template for the
amplification of L2.
After the amplification of fragments L1 and L2, a second PCR reaction was
performed. T1 and L2 were used as template DNA, and primer 1 and primer 4 were
used for the PCR amplification. As T1 and L2 had complementary sequences at their 3’
and 5’ end, respectively, a cDNA encoding TMD0(MRP1)L0(MRP2) was obtained. The
fragment contained Bam HI restriction sites both ends, which were used for cloning into
the pGEM-7Zf  plasmid vector. Sequence analysis showed that the amplified fragment
did not contain mutations.
The T1L2 fragment was isolated from the amplified pGEM-7Zf expression
vector after digestion with Bam HI, and cloned into the Bam HI digested retroviral
pBabe-puro-CMV vector containing the strong viral CMV promoter upstream of the
cloned cDNA and a puromycin resistance gene. MDCKII-T1L2 and MDCKII-
T1L2+∆ MRP1 stable cell lines were generated by retroviral transduction as described in
4.3.1. For selection of clones expressing the transduced constructs, cells were grown in
medium containing puromycin and positive clones were isolated (fig. 4.22, panel B).93
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Fig. 4.22. Generation of the chimeric TMD0(MRP1)L0(MRP2) cDNA  by overlap PCR.
A. Primer 1 initiates at bp 169 of MRP1, primer 2 at bp 702 (MRP2), primer 3 at bp 769 (MRP1) and
primer 4 at bp 900 (MRP2). Primer 1 and primer 4 contain the Bam HI restriction site.
B. Example of Western Blot analysis of TMD0(MRP1)L0(MRP2) clones isolated after selection with
Puromycin. The blot was incubated with anti-MRP2 mAb M2I4.94
4.6.2  Western blot analysis of MDCKII-TMD0(MRP1)Lo(MRP2) and
of MDCKII-TMD0(MRP1)L0 (MRP2)+∆MRP1 lysates
The selected clones of MDCKII-TMD0(MRP1)L0(MRP2) and MDCKII-
TMD0(MRP1)L0(MRP2)+∆ MRP1 cells were analyzed by Western Blot analysis.
The Western blot in fig. 4.23 (panel A) was incubated with the anti MRP2 mAb
M2I4, recognizing an epitope within the cytoplasmic loop of MRP2 between aa 215 and
310. Proteins from lysates of both cell lines were size fractionated in an 11%
polyacrylamide denaturing gel. The amount of chimeric protein produced by the two
cell lines is similar (panel A, lanes 1 and 2).
In panel B the same lysates as in panel A were size fractionated. The blot was
incubated with mAb MRPm6 to verify the presence of ∆ MRP1 in MDCKII-
TMD0(MRP1)L0(MRP2)+∆ MRP1 cells. ∆ MRP1 in these cells was detectable as it can
be seen in panel B, lane 2. As expected no ∆ MRP1 protein was detectable in the wild
type MDCKII cells expressing T1L2.
Fig. 4.23. Western blot analysis of MDCKII-TMD0(MRP1)L0(MRP2) and of MDCKII-TMD0(MRP1)L0
(MRP2)+∆ MRP1 lysates.95
A. Detection of TMD0(MRP1)L0(MRP2) in parental cells and in ∆ MRP1 expressing MDCKII cells by
western blot analysis. Twenty µg of protein were size-fractionated on an 11% polyacrylamide gel. After
electroblotting the protein was revealed using anti-hMRP2 mAb M2I4.
B. Detection of ∆ MRP1 in TMD0(MRP1)L0(MRP2) expressing MDCKII-∆ MRP1 cells. Twenty µg of
protein were size-fractionated on a 7,5% polyacrylamide gel. After electroblotting  ∆ MRP1 was detected
using mAb MRPm6.
4.6.3  Glycosylation state of TMD0(MRP1)L0(MRP2) in MDCKII and
in MDCKII-∆MRP1 cells.
In order to verify the glycosylation state of TMD0(MRP1)L0(MRP2) I treated
cell lysates containing the chimeric protein with N-glycosidase F and with
Endoglycosidase-H. Endoglycosidase-H only recognizes high-mannose and hybrid-type
N-glycans and cleaves between the two N-acetylglucosamine residues in the core of the
oligosaccharide, generating a truncated sugar molecule with one N-acetylglucosamine
residue remaining on the asparagine. In contrast, as shown above (fig. 4.17, panel A), N-
glycosidase F removes complex oligosaccharide (fig. 4.24, panel A).
After the deglycosylation reaction, proteins were analyzed by Western blot
analysis. Fig. 4.24 (panel B), shows the deglycosylation of TMD0(MRP1)Lo(MRP2)
expressed in MDCKII-∆ MRP1 (lanes 1 and 2) and in MDCKII cells (lanes 3 and 4).
Membrane extracts were treated with N-glycosidase F as described.
TMD0(MRP1)Lo(MRP2) was glycosylated in both cell lines as demonstrated by the
detection of a low molecular weight band after glycosidase treatment. After treatment,
the signal revealed for the protein by Western blot analysis changed to an apparent
molecular weight of approximately 28 kDa.
Treatment of MDCKII and MDCKII-∆ MRP1 lysates with Endoglycosidase-H
(fig. 4.26, panel C) gave similar results as with N-glycosidase F. In lanes 1 and 2 the
Western blot of Endoglycosidase H treated lysates from MDCKII-
TMD0(MRP1)Lo(MRP2)+∆ MRP1 cells is shown, and in lanes 3 and 4, lysates from
MDCKII cells expressing the chimeric protein. Corresponding to the results of
deglycosylation with N-glycosidase F, after treatment with Endoglycosidase-H the
apparent molecular weight of the mutant protein decreased to about 28 kDa. As a
control I incubated cell lysates from MDCKII-TMD0L0 cells with Endoglycosidase-H.96
After incubation, the proteins were size fractionated in a 7,5% polyacrylamide gel
(panel D, lanes 1 and 2). TMD0L0 was not affected by this enzyme, confirming that
TMD0L0 is not localized in the endoplasmic reticulum.
A
R1 =  Fucose  α -1,3
R2 =  Oligosaccharide N-Glycosidase F
protein   Asn   GlcNAc R2 GlcNAc
R1
Endoglycosidase H
Fig. 4.24. Glycosylation of TMD0(MRP1)L0(MRP2) in parental MDCKII and in MDCKII-∆ MRP1 cells.97
A. Enzymatic cleavage by N-glycosidase F and Endoglycosidase H.
B. Western blot analysis of membrane extracts of TMD0(MRP1)L0(MRP2)+MDCKII-∆ MRP1 cells and
TMD0(MRP1)L0(MRP2)-MDCKII cells, treated (lanes signed with +) with N-glycosidase F. Membranes
were incubated for 1h with N-glycosidase F at 37°C. As control, untreated membranes (lanes signed with
-) are shown. Proteins were size-fractionated in an 11% polyacrylamide denaturing gel. After
electroblotting proteins were detected with M2I4 antibody.
C. Treatment with Endoglycosidase-H of lysates from TMD0(MRP1)L0(MRP2)+MDCKII-∆ MRP1 cells
and TMD0(MRP1)L0(MRP2)-MDCKII cells. Membranes were incubated for 1h with Endoglycosidase-H
at 37°C. Lanes signed with - indicate untreated controls. As in (A), proteins were size-fractionated in an
11% polyacrylamide denaturing gel, and after electroblotting they were revealed with mAb M2I4.
D. Incubation of MDCKII-TMD0L0 cell lysates with Endoglycosidase-H, at same conditions as in (B).
The lane signed with - indicates untreated lysates. Proteins were size-fractionated in a 7,5%
polyacrylamide denaturing gel, and after electroblotting they were revealed with mAb MRPr1.
4.6.4  Immunolocalization of TMD0(MRP1)L0(MRP2) in MDCKII and
in MDCKII-∆MRP1 monolayers.
By indirect immunocytochemistry I analyzed if the substitution of L0 of MRP1
for L0  of MRP2 in TMD0L0  affected its subcellular localization.
TMD0(MRP1)L0(MRP2)was detected with the anti MRP2 mAb M2I4 in MDCKII and
MDCKII-∆ MRP1 monolayers.
Panel A of fig. 4.25 shows that TMD0(MRP1)L0(MRP2) is not routed to the
plasma membrane in MDCKII cells.
In panel B the localization of the chimeric protein in MDCKII-∆ MRP1
monolayers is demonstrated. Like the result shown in panel A, the protein was localized
intracellularly. The picture on the right side shows the immunolocalization of ∆ MRP1
in the same monolayers. In contrast to cells co-expressing TMD0L0 and ∆ MRP1, the
subcellular localization of ∆ MRP1 was not affected in cells co-expressing ∆ MRP1 and
TMD0(MRP1)L0(MRP2). Immunolocalization of ∆ MRP1 was performed using the
antiMRP1 mAb QCRL3.98
Fig. 4.25. Immunolocalization of TMD0(MRP1)Lo(MRP2)in MDCKII and in MDCKII-∆ MRP1
monolayers.
A. Immunolocalization of TMD0(MRP1)L0(MRP2)in MDCKII monolayers.
B. Immunolocalization of TMD0(MRP1)L0(MRP2) in MDCKII-∆ MRP1 monolayers.
TMD0(MRP1)L0(MRP2) was detected with anti MRP2 mAb M2I4, ∆ MRP1 was detected with mAb
QCRL3 (green signals). Nucleic acids were counterstained with propidium iodide. In the schematic
representation of the constructs, parts in dark gray indicate MRP1, parts in light gray indicate MRP2. The
TMD0(MRP1)L0(MRP2) molecule is abbreviated as T1L2.99
5  DISCUSSION
The N-terminal domain TMD0L0 (amino acids 1-282) of MRP1 consists of the first
transmembrane domain TMD0 and the cytoplasmic linker L0. Previously, Bákos et al.
(1998, 2000) examined the function of the TMD0L0 domain and found that the linker
peptide L0 is required for transport and might contain a signal required for routing to the
lateral plasma membrane of the protein. The focus of this thesis was to investigate the
role of the N-terminal domain L0 of MRP1 in transport and routing to the lateral plasma
membrane in polarized MDCKII cells. As MRP1 may cause clinical chemotherapy
resistance in human tumors (Hipfner et al., 1999; Borst and Oude Elferink, 2002),
information regarding its key functional domains and the identification of small specific
peptide regions will help to design efficient inhibitors for this drug pump. The
elucidation of the mechanisms of action of MRP1 might contribute to the understanding
of the multidrug resistance phenotype of cancer cells, potentially allowing the design of
mechanism-based drugs.
I searched for regions that are important for routing of MRP1 to the basolateral
plasma membrane by expression and co-expression of various MRP1 mutants in
polarized MDCKII cells. An evolutionary conserved α -helix within the linker loop L0
was identified that is important for the transport function of MRP1, since a mutant
lacking this helix did not mediate efflux of DNP-GS and daunomycin. Routing of this
protein was not affected by this deletion (fig. 4.6), indicating that the function of MRP1
as transporter is not necessarily coupled to its ability to route to the lateral membrane. If
the intracellularly localized core of MRP1, ∆MRP1, was co-expressed with the isolated
L0 peptide in MDKCII cells, I found that L0 was routed to the lateral membrane (fig.
4.10). L0 in these cells was probably rapidly degraded, as I was not able to isolate clones
stably expressing L0. I therefore established MDCKII cell lines expressing the TMD0L0
region alone or together with ∆MRP1 (figures 4.12 and 4.18). I found that in cells
strongly overproducing TMD0L0 part of the molecules were localized laterally. In
MDCKII-TMD0L0+∆MRP1 cells both deletion fragments were routed to the lateral
plasma membrane, supporting the hypothesis that the L0 region contains information
required for lateral routing. The co-expression of TMD0L0 with ∆MRP1 also resulted in100
increased transport of the anthracycline daunorubicin and the organic anion DNP-GS.
Transport was similar to that observed in MDCKII-MRP1 cells (figure 4.19), suggesting
that TMD0L0 and ∆MRP1 dimerize with each other and do not have to be covalently
bound in order to form a functional transporter. Further support for dimerization of the
two co-expressed mutant fragments was obtained in co-immunoprecipitation
experiments that demonstrated that TMD0L0 was binding to ∆MRP1 (fig. 4.21).  To
investigate whether L0 from MRP2 could substitute for L0  of MRP1, a chimeric
molecule was constructed consisting of TMD0 of MRP1 and L0 of MRP2. In MDCKII
cells the resulting protein was localized in an intracellular compartment, probably the
endoplasmic reticulum (figures 4.24 and 4.25).
5.1  The N-terminal region of MRP 1
The N-terminal transmembrane domain TMD0 is found in several MRP family
members and although this region shows a low overall amino acid identity among these
proteins, it is structurally conserved in evolution (Tusnady et al., 1997). MRP1 was the
first ABC transporter in which topology predictions suggested the presence of this
domain and it was speculated that it might be essential for transport activity. It is
evident from our experiments that L0 is essential for the function of MRP1, but the role
of TMD0 is not clear. The possibility that TMD0 has no function is improbable, since
this domain is evolutionary conserved. TMD0  could have a regulatory role by
interacting with other membrane proteins, be required for the stabilization of the
protein, be important for the efficient transport of some substrates, or contribute to
proper protein routing in other cells than canine kidney derived MDCKII cells. That
TMD0 may have a stabilizing role is suggested by the fact that despite various attempts,
establishing cell lines stably expressing L0 failed. I was able to establish, however,
MDCKII cell lines stably expressing TMD0L0. The hypothesis that TMD0 plays a role
in routing in some MRP orthologs was supported by recent findings of Mason and
Michaelis (2002). These authors showed that the first transmembrane domain plays a
critical role in trafficking to the vacuolar membrane of Ycf1p, a yeast homolog of
MRP1 localized in the vacuolar membrane. Fragments of Ycf1p were expressed101
separately or together, following a similar approach as used to characterize the various
MRP1 domains (Bàkos et al., 1998, 2000; Gao et al., 1998; this thesis). In contrast to
what I found for MRP1, the first transmembrane domain was essential for routing of
Ycf1p to the vacuolar membrane. Similarly Mateus et al. (2002) demonstrated recently
that TMD0 of MRP2 is required to remain stably localized in the apical membrane or for
the routing of MRP2 to the apical plasma membrane in MDCKII cells. These data
together indicate that at least in some MRP family members, the first transmembrane
domain is required for proper the routing of the protein.
Yang et al. (2002) constructed mutant forms of MRP1 in which N-terminal
cysteine residues at position 7 or 32 were mutated to an alanine. Mutation of Cys7
resulted in a strong decrease in the Vmax for transport of LTC4 whereas the Km was
hardly affected. Mutation of Cys7 also resulted in loss of resistance against doxorubicin,
vincristine, VP-16 and colchicine. It was shown that mutation of Cys7 resulted in a
change in the N-terminal conformation of MRP1. A role of TMD0 in transport activity
was also suggested by experiments by Gao et al. (1998). They found a loss of transport
activity as a result of the deletion of the first transmembrane α -helix of MRP1. These
data suggest that the N-terminus of MRP1 is important in maintaining the proper
structure of MRP1 and that mutations disturb the proper folding of the whole molecule.
Probably removal of the whole TMD0 domain restores transport activity (Bàkos et al.,
1998), as the mutated region no longer interferes with the L0∆MRP1 region.
5.2  Identification of an amphipathic αααα -helix within L0
The presence of the L0 domain is characteristic for all known MRP family
members including the sulfonyl urea receptor (SUR1/2, ABCC8 and -9) and CFTR
(ABCC7). Our aim was to examine the apparent important role of this region in plasma
membrane targeting and transport of MRP1.
Co-expression  in Sf9 cells of the non-functional core of MRP1, ∆MRP1, with
the L0 fragment resulted in an active transporter with similar transport characteristics as
wild type MRP1 (Bàkos et al., 2000). This indicates that a covalent linkage between102
∆MRP1 and the L0 region is not required. It was found that the isolated L0 peptide was
attached to membranes and could only be solubilized by treatment with urea or
detergents. Detergents typically solubilize proteins with hydrophobic regions interacting
with the phospholipid bilayer. The computer-based secondary structure predictions
shown in fig. 1.6 suggests that the L0 region includes two alpha-helical regions, one of
which, between amino acids 221-233, is an amphipathic helix conserved in all members
of the MRP family. This amphipathic helix may produce hydrophobic interactions with
the lipid bilayer of the cell membrane or with hydrophobic regions of other membrane
proteins. The identification of an α -helix may explain the binding of the L0 peptide to
the membrane. In amphipathic helices with a structure corresponding to the predictions
shown in figure 1.6, the hydrophobic amino acids of the helix are exposed to the lipid
inner core of the membrane. At the bilayer interface rings of tryptophan and tyrosine
residues are present and flanking these residues hydrophilic amino acids are localized.
This might be the molecular basis for the interaction between the amphipathic helix in
L0 and the plasma membrane.
A mutant MRP1 molecule containing a ten amino acid deletion (∆223-232) was
constructed in order to analyze the role of the amphipathic alpha-helical region in
plasma membrane routing or function of MRP1. Tunicamycin treatment demonstrated
that MRP1∆(223-232) is N-glycosylated in MDCKII cells (fig. 4.4). MRP1∆(223-232)
appears to be glycosylated like the wild-type protein, suggesting that the two proteins
might follow the same post-translational pathway. That this may indeed be the case is
indicated by the lateral localization of MRP1∆(223-232) in MDCKII monolayers as
detected by CLSM (fig. 4.5).
In figure 4.7 it is demonstrated that the α -helix is required for the transport
function of MRP1. Similarly, it was demonstrated (Mason and Michaelis, 2002) that the
homologous amphipathic helical region in L0 of the yeast protein Ycf1p is important for
transport activity. Taken together with the results shown in figure 4.5, this indicates that
basolateral routing and transport activity of MRP1 are not coupled. This is probably
also true for MRP2, as Mateus et al. (2002) found that an MRP2 mutant lacking the
TMD0 domain was not routed to the apical plasma membrane in MDCKII cells, but still
able to transport LTC4.103
Similar to Bàkos et al. (1998) who constructed an MRP1 fragment extending
from amino acid 204 to the C-terminus, Gao et al. (1998) constructed an MRP1 mutant
also lacking the first transmembrane domain TMD0 but starting at amino acid 229. In
contrast to the mutant starting at amino acid 204, the mutant of Gao et al. did not show
any transport activity. This is most likely explained by the fact that in this mutant the α -
helical region is disrupted. Critical amino acids for the function of MRP1 were
identified by others in transmembrane helices in the C-terminal transmembrane region
(Haimeur et al., 2002; Conrad et al., 2002; Zhang et al., 2001; Ito et al., 2001). In order
to explain why the absence of the helix in L0 compromises the function of the protein it
is possible to speculate that it interferes with conformational changes occurring in the
protein during the transport cycle.
5.3  Routing to the plasma membrane in polarized cells
Polarity in epithelial cells results from domain-specific sorting of proteins. Most
newly synthesized proteins are believed to be sorted at the level of the Golgi complex to
either the apical or the basolateral membrane after recognition of signals located within
the protein itself (Caplan, 1997). Such specific signals are required for inclusion of
proteins into vesicles destined for the apical or basolateral membrane. In many cases,
once delivered to the appropriate domain, proteins are anchored to or in the membrane
by interactions with the cytoskeleton or with other membrane proteins (Yeaman et al.,
1999).
A family of adaptor protein complexes (AP) can mediate incorporation into
transport vesicles by interacting with the sorting signals presented in cytosolic domains
of the transmembrane proteins, once they are matured in the Trans Golgi Network
(TGN; Boman et al., 2001). Four adaptor protein complexes, AP1-4 have been
characterized (Bonifacino and Dell’Angelica, 1999; Robinson and Bonifacino, 2001).
Recently is was demonstrated (Simmen et al., 2002) that AP4 can bind different types
of cytosolic signals known to mediate basolateral transport in epithelial cells. Under the
apical sorting mechanisms, clustering into cholesterol and sphingolipid-rich, detergent104
insoluble microdomains (rafts) has been speculated to be important for the formation of
vesicles from the TGN for some membrane proteins (Simons and Ikonen, 1997).
Nevertheless the raft hypothesis is still very controversial It has been demonstrated that
the apical targeting of mutant forms of hemagglutinin (Lin et al., 1998) and of serpins
(Larsen et al., 2002) in MDCKII cells takes place independently from their association
with rafts.
Several different basolateral sorting signals have been identified. In many cases
they have been located in the cytoplasmic tail of the protein. The determinant for
basolateral sorting may coincide with  tyrosine-based or dileucine-based endocytosis
signals, which are well known as clathrin-coated pit internalization signals (Matter and
Mellman, 1994). It has been reported that the basolateral sorting of the transferrin
receptor TfR is mainly determined by the GDNS sequence downstream of the YTRF
endocytosis/coated pit localization signal (Dargemont et al., 1993; Odorizzi and
Trowbridge, 1997a). Most of the tyrosine-based sorting signals fit to the consensus
sequence YXXØ, where Y is a tyrosine, X any amino acid and Ø a hydrophobic amino
acid (Ohno et al., 1995, 1999; Boll et al., 1996; Dell'Angelica et al., 1997; Aguilar et
al., 2001). A recent example is the localization of the basolateral routing signal of the
chicken AE1-4 anion exchanger in MDCK cells, which demonstrated to be dependent
upon a tyrosine and a leucine residue that resides within the sequence YVEL, matching
the YXXØ motif (Adair-Kirk et al., 2003). As adaptor protein (AP) complexes of
clathrin coats interact, at least in vitro, directly with sorting signals that contain critical
tyrosine residues (in the context of the consensus sequence YXXØ) it had been
hypothesized that an AP- or AP-like complex may play a similar role in basolateral
sorting in epithelial cells (Hunziker et al., 1991).
Alternative to tyrosine dependent signals, a dileucine motif has been identified
for the first time in the cytoplasmic tail of the mouse macrophage Fc receptor isoform
II-B2 (FcRII-B2). Another signal, identified in the IgG Fc receptor and the human
invariant chain, only requires a central di-hydrophobic doublet (LL and ML,
respectively) (Hunziker and Fumey, 1994; Odorizzi and Trowbridge, 1997b). The LL
signal is required both for basolateral sorting and endocytosis (Matter et al., 1994;
Hunziker and Fumey, 1994). Another type of dileucine motif identified in the105
endoprotease furin, requires an additional upstream acidic amino acid (Simmen et al.,
1999). A highly conserved dileucine motif is responsible for the basolateral targeting of
E-cadherin, a major adherens junction protein of epithelial cells (Miranda, 2001).
Interestingly the cytoplasmic routing signal of the water channel Aquaporin 4 (AQP4) is
composed of two independent basolateral sorting signals. One signal consists of a
dileucine-based motif preceded by a cluster of acidic amino acids (ETEDLIL), while the
other involves the tyrosine-based motif (YMEV) (Madrid et al., 2001). Likewise two
discontinuous motifs responsible for basolateral sorting of the human Interleukine-6
(IL-6) receptor were identified: a tyrosine-based motif (YSLG) and a dileucine-type
motif (LI) (Martens et al., 2000).
Alternatively, basolateral routing motifs can be unrelated to coated-pit
internalization signals, dependent or independent of critical tyrosine residues (Aroeti et
al., 1998). Also other basolateral sorting signals, different form the classical tyrosine
and dileucine motifs have been identified (Le Gall et al., 1997; Distel et al., 1998). The
presence of a bipartite basolateral sorting motif composed by the amino acids QETE
and (EP)LT has been recognized in the cytoplasmic juxtamembrane region of the
receptor tyrosine kinase ERBB2 (Dillon et al., 2002).
Sorting and/or retention of proteins in their membrane domains can also be
mediated by PDZ domain containing proteins. PDZ domains are conserved 70-90 amino
acid domains with a defined secondary structure (Doyle et al., 1996), that bind to short
peptide sequences at the C-terminus of other proteins, which are called PDZ-interacting
domains. This interaction requires the sequence (T/S)XV, where at the  –2 position
serine or threonine residues are permitted, at position –1 any amino acid and at position
0, the C-terminus, a valine or another amino acid with a hydrophobic side-chain. PDZ
proteins are cytosolic, generally restricted to specific subcellular domains as synapses,
tight junctions, or the apical or the basolateral cell surface. Their function is to localize
their ligands to the appropriate subcellular domain, e.g.  anchoring and clustering
transmembrane proteins or recruiting cytosolic proteins to membrane complexes
(Fanning and Anderson, 1999).
A PDZ interaction is required for the polarization of CFTR to the apical plasma
membrane (Moyer et al., 2000). Recently it was demonstrated that in this case the PDZ106
interacting domain of CFTR does not mediate apical sorting but retention of the protein
in the plasma membrane. Two PDZ proteins belonging to the same gene set, LIN-10
and LIN-7 are responsive for the basolateral sorting of the EGF receptor (Whitfield et
al., 1999) and of the potassium channel Kir 2.3, respectively (Olsen et al., 2002). A
PDZ protein was found to interact with the C-terminus of MRP2 (Kocher et al., 1999),
but mutation analyses by Nies et al. (2002) and Mateus et al., (2002) found that the
apical routing of MRP2 is independent of a PDZ interaction. Recently, it was shown
that in knock-out mice lacking the PDZK1 protein, the routing of Mrp2 was not
impaired (Kocher et al., 2003).
5.4  Role of the cytoplasmic linker L0
By co-expression of L0 with ∆MRP1 in MDCKII cells, it was found that L0 was
routed to the lateral plasma membrane (fig. 4.10), most likely together with ∆MRP1. It
was shown (Bàkos et al., 2000) that when the two peptides were co-expressed in Sf9
cells a functional MRP1 protein was obtained. These results strongly suggest that the
isolated L0 peptide is able to associate with ∆MRP1 and that, consequently, the protein
regains its function and is routed to the lateral membrane. Transport by the co-produced
proteins could not be measured in MDCKII cells, as for technical reasons it was not
possible to isolate single clones. To obviate the difficulty of generating an MDCKII-L0
cell line, I cloned the complete N-terminal fragment TMD0L0 (amino acids 1-281) and
expressed it in MDCKII cells. Bàkos et al. (1998) detected by indirect
immunofluorescence the presence of TMD0L0 in large intracellular vesicles. In this
thesis, however, partial lateral localization of the polypeptide was observed by CLSM
(fig. 4.12), a finding, which was confirmed by the cell surface biotinylation experiments
(fig.4.15). An explanation for this incongruity is that the MDCKII- TMD0L0 cell line I
analyzed produced relatively high amounts of the TMD0L0 peptide (fig. 4.11, panel B).
The protein is probably rapidly turned over, as it is only a relatively small non-
functional fragment. The lateral staining is possibly the result of a equilibrium between
endocytosis and expression rate. I therefore can not rule out that the partial lateral
localization of the TMD0L0 polypeptide is an artifact of the relatively high expression in107
the clone analyzed. A more attractive hypothesis, however, is that a basolateral routing
signal is present in TMD0L0. Detailed mutagenesis studies are required to discriminate
between these two possibilities.
5.5  Co-expression of TMD0L0 and ∆MRP1 in MDCKII cells
A stable MDCKII cell line co-expressing TMD0L0 and ∆MRP1 was selected. The
first indication that TMD0L0 had an effect on ∆MRP1 was the presence of an additional
band running at a somewhat higher apparent molecular weight in Western blots with
MDCKII-TMD0L0+∆MRP1 lysates (fig. 4.16). Enzymatic digestion with N-glycosidase
F showed that this additional band was due to glycosylation of ∆MRP1 (fig. 4.17).
Peptide-N-glycosidase F from Flavobacterium meningosepticum cleaves almost all N-
glycans from glycoproteins (Tarentino and Plummer, 1994). It is interesting to note that
while TMD0L0 is sensitive to the treatment with N-glycosidase F (fig. 4.17, panel C), it
is not affected by the activity of Endoglycosidase H (fig. 4.24, panel D).
Endoglycosidase H (Endo H) from Streptomyces plicatus only releases high-mannose
and hybrid type glycans, non-mature intermediates formed during the processing of
complex oligosaccharides on glycoproteins in the Golgi. That Endoglycosidase H fails
to remove sugar residues from TMD0L0 provides an additional indication that this
protein moves through the secretory pathway to the plasma membrane.
∆MRP1 is routed to the lateral plasma membrane in the presence of TMD0L0
(fig. 4.18 panel B) and the co-expression of the two truncated mutants results in a
functional DNP-GS and daunomycin transporter (fig. 4.19). This is in accordance with
data published by Bàkos et al. in 1998 showing that the co-expression of these truncated
forms of MRP1 in Sf9-derived vesicles results in full MRP1-like ATP dependent
transport activity. Gao et al. (1998) also found independently that when the two half-
molecules were co-expressed transport activity was restored. In an analogous way, it
was found that the co-expression of a truncated mutant extending from the N-terminus
to the first ABC cassette with the complementary half protein resulted in an active
transporter in insect cells (Gao et al., 1996). A similar situation was found in yeast,108
where co-expression of parts of Ycf1p requires results in an active protein (Mason and
Michaelis, 2002). Some ABC transporters are half-molecules, containing only one
membrane spanning domain and one nuclear binding domain. These half-transporters
function either as homo- or heterodimers. Examples are the peptide transporter TAP1
and TAP2, which acts a heterodimer (Trowsdale et al., 1990; Shepherd et al., 1993) and
BCRP, which acts as a homodimer (Kage et al., 2002). The separation or fusion of
functional domains may not be of importance for the activity of ABC transporters. The
data reported in figures 4.17, 4.18 and 4.19 suggest that the two proteins recognize each
other as portions of wild-type MRP1 either in the plasma membrane or in the secretory
pathway en route to the plasma membrane. The latter hypothesis is the most likely one
as ∆MRP1 is only glycosylated if co-expressed with TMD0L0. That TMD0L0  and
∆MRP1 physically interact is shown by the result shown in fig. 4.21; TMD0L0 is co-
immunoprecipitated with ∆MRP1 in lysates from MDCKII-TMD0L0+∆MRP1 lysates
using mAb QCRL3, an antibody recognizing an epitope at the C-terminus of MRP1.
Results obtained by Loo and Clarke (1995) by co-immunoprecipitations indicate as well
that there are specific noncovalent associations between the various domains of P-
glycoprotein. Not only an association between the two transmembrane domains was
detected, but unexpectedly also between the nucleotide-binding domains and between
the nucleotide-binding domains and the transmembrane domains of the same half-
protein. These results suggest that structure and function of P-glycoprotein are
influenced by noncovalent interactions between the domains of the protein. The authors
propose that noncovalent interaction between the domains of P-glycoprotein may
contribute to structure and function of P-glycoprotein. Gu et al. (2001a) analyzed the
trafficking and activity of Adenylyl cyclases. These proteins possess similar structures
as ABC transporters. They consist of two tandem six-transmembrane segments
containing domains, each followed by a highly homologous ATP-binding cytosolic
loop. It was demonstrated by co-immunoprecipitation of various truncated and mutated
molecules, and functional assays that cooperation between the two intact
transmembrane domains was essential and sufficient to target the enzyme to the plasma
membrane of the cell.109
5.6  A comparison of MRP1 with the homologous protein MRP2
MRP1 and MRP2 transport a more or the less overlapping range of
chemotherapeutic drugs (Borst et al., 2000). While MRP1 is routed to the lateral
membrane in polarized cells, MRP2 is routed to the apical membrane. Mateus et al.
(2002) constructed similar MRP2 mutants as those described in this thesis. Neither the
N-terminal TMD0L0  nor ∆MRP2, the C-terminal core, are routed to the plasma
membrane. It is interesting to note that the construct L0∆MRP2 was not sorted to the
apical membrane, but found in endosomes (Mateus et al., 2002). In vitro uptake
experiments, however, with vesicles made from baculovirus infected Sf9 cells
producing L0∆MRP2 showed that the protein was able to transport LTC4. This indicates
that like in the case of MRP1 routing and transport activity are not linked. In contrast to
what was found for MRP1, L0 was not sufficient for routing of MRP2 to the plasma
membrane. The TMD0 domain of MRP2 is clearly important to for routing to the apical
plasma membrane. Considering that all TMD0L0 of MRP2 was detected intracellularly
if expressed alone, it is possible that MRP2 contains multiple signals required for
routing. I can not exclude that this is also the case for MRP1 as only a small fraction of
the TMD0L0 fragment of MRP1 was routed basolaterally.
5.7  Construction of a chimeric MRP1/MPR2 peptide
The norepinephrine transporter (NET) is localized predominantly in the
basolateral plasma membrane, while the dopamine receptor (DAT) is localized in the
apical membrane (Gu et al., 1996). Both proteins share 67% overall amino acid
sequence identity. Recently, Gu et al. (2001b) characterized by immunocytochemistry
and transport experiments chimeric proteins consisting of fragments of NET and DAT.
These studies resulted in the identification of a dileucine basolateral sorting signal in the
N-terminal cytoplasmic tail of NET. Using a similar approach Dunbar et al. (2000)
described the routing behavior of chimeric proteins containing part of the Na/K ATPase
α   subunit (basolateral localization) and of the H,K-ATPase α   subunit (apical110
localization). The two loops flanking the fourth transmembrane helix of the H,K-
ATPase but also the fourth helix itself were able to redirect the Na/K ATPase to the
apical membrane. These experiments revealed the complexity that routing signals can
have in polytopic transporters. Following a similar approach I constructed an
MRP1/MRP2 chimeric mutant analog to TMD0L0 (figures 4.22-25), consisting of the N-
terminal transmembrane domain TMD0 of MRP1 and the cytosolic loop L0 of MRP2. In
lysates made from MDCKII cells producing this peptide the chimeric polypeptide was
deglycosylated by N-glycosidase F and Endoglycosidase H (fig. 4.24). This indicates
that this mutant probably does not pass the quality control in the endoplasmic reticulum.
This finding was confirmed by the immunolocalization of the mutant protein, indicating
that staining was restricted to the cytoplasm (fig. 4.25).
 The intracellular localization of TMD 0 (MRP1) L 0 (MRP2) could be due to
misfolding of the peptide. The deglycosylation of the protein by Endoglycosidase H
showed that the maturation process of the carbohydrate chains was not complete. For
certain proteins, accurate N-glycosylation is required for proper folding and misfolded
polypeptides are retained in the ER (reviewed in Ma and Hendershot, 2001), where they
are degraded by proteasomes. It has been demonstrated by Simons and Wardinger-Ness
(1990) that in polarized cells apical and lateral transmembrane proteins are contained in
the same rough ER and Golgi vesicles along the secretory pathway. The sorting to
specific transport vesicles of apical and basolateral directed proteins occurs within the
trans  Golgi network. Therefore, an alternative explanation for the intracellular
localization of TMD0 (MRP1) L0 (MRP2) is that the transit of the protein through the
secretory pathway is blocked, as it does neither contain basolateral nor apical dominant
sorting signals. To identify the signals responsible for the basolateral routing of MRP1,
more detailed mutational analyses are required.111
6  ABBREVIATIONS
APS ammonium  persulfate
AZT-MP azidothymidine monophosphate
BBB blood-brain barrier
BSA  bovine serum albumine
BSO buthionine sulfoximine
CDNB 1-chloro-2,4-dinitro-benzene
CLSM confocal laser scanning microscopy
CMV cytomegalovirus
DMEM Dulbecco’ s modified
DMSO dimethil sulfoxyde
DNP-GS dinitro-phenyl-glutathione
DTT Dithiothreitol
EA ethacrynic acid
ECL enhanced chemiluminescence
EDTA Ethylenediamine-N,N,N',N'-tetraacetic acid
FITC Fluorescein isothiocyanate
HA Hemagglutinin
HBSS  Hanks buffered saline solution
HEPES 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic  acid
Kb kilo Bases
kDa kilo Dlaton
LB medium Luria-Bertani medium
Luminol 5-Amino-2,3-dihydro-1,4-phthalazinedione
mAb monoclonal antibody
MDCKII Madin Darby canine kidney type II
MMULV Moloney murine leukemia virus112
MTX methotrexate
NEM-GS N-ethylmaleimide glutathione
OD optical density
PBS Phosphate buffered saline
PCR Polymerase chain reaction
PMSF phenylmethylsulfonyl  fluoride
SDS Sodium Dodecyl Sulfate-Lauryl
Sf9 Spodoptera frugiperda insect cells
TEMED N,N N',N'-Tetramethylethylenediamine113
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